var title_f26_47_27376="Hidradenitis suppurativa and surgical unroofing";
var content_f26_47_27376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa and surgical unroofing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical unroofing is the primary therapy for severe and extensive hidradenitis suppurativa. This picture shows the beveled edges of the wound following the unroofing of the inflamed nodule. Ferric chloride was used to control hemostasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27376=[""].join("\n");
var outline_f26_47_27376=null;
var title_f26_47_27377="TEE right atrial appendage";
var content_f26_47_27377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Right atrium and appendage on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Horizontal (0&ordm;) imaging plane with advancement of the probe towards the gastroesophageal junction with slight anterior rotation demonstrates the right atrium (RA) and right atrial appendage (RAA, panel A). In panel B, the probe is rotated posteriorly and the RA and coronary sinus (CS) are seen. With further advancement of the probe (panel C), the right ventricle (RV) and tricuspid valve (TV) are seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27377=[""].join("\n");
var outline_f26_47_27377=null;
var title_f26_47_27378="KS invasion of bronchial wall";
var content_f26_47_27378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endobronchial Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows dark, hemorrhagic Kaposi sarcoma tissue (arrow) lining and invading the bronchial mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27378=[""].join("\n");
var outline_f26_47_27378=null;
var title_f26_47_27379="Minoxidil (topical): Drug information";
var content_f26_47_27379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minoxidil (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/58/33699?source=see_link\">",
"    see \"Minoxidil (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8774870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rogaine&reg; Extra Strength for Men [OTC];",
"     </li>",
"     <li>",
"      Rogaine&reg; for Men [OTC];",
"     </li>",
"     <li>",
"      Rogaine&reg; for Women [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8774871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Gain&reg;;",
"     </li>",
"     <li>",
"      Rogaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8774876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8774956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Alopecia:",
"     </b>",
"     Topical: Apply twice daily; 4 months of therapy may be necessary for hair growth.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8774960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rogaine&reg; for Men: 5% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 2% (60 mL); 5% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rogaine&reg; Extra Strength for Men: 5% (60 mL) [contains ethanol 30% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rogaine&reg; for Women: 2% (60 mL) [contains ethanol 60% v/v]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8774872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8774915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of alopecia androgenetica in males and females",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8774929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Dermatologic: Local erythema (6%), pruritus (6%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8774925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to minoxidil or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8774926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hair color changes: Changes in hair color and/or texture may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart disease: Due to potential systemic absorption with subsequent fluid/electrolyte changes, a careful risk:benefit assessment should be performed in patients with heart disease before the use of topical minoxidol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other medications applied to scalp: Topical minoxidil should not be used when other medications are being applied ot the scalp.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical solution: Flammable; keep away from fire or flame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes, mouth, nose, or other mucous membranes. Do not use if scalp is red, inflamed, infected, or painful. Not intended for frontal baldness or receding hairline or in patients with no family history of hair loss. Sudden, unexplained, or \"patchwork\" hair loss should be carefully evaluated prior to use. Not for use in children &lt;18 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8774932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8774921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9773197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral dosing, minoxidil is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8774962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Rogaine Mens External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $16.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Rogaine Mens Extra Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $27.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Minoxidil External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 mL): $25.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rogaine Extra Strength for Men External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 mL): $26.88",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alopexy (BE, IL);",
"     </li>",
"     <li>",
"      Alopexyl (FR);",
"     </li>",
"     <li>",
"      Alostil (FR);",
"     </li>",
"     <li>",
"      Aloxid (ID);",
"     </li>",
"     <li>",
"      Apo-Gain (MY);",
"     </li>",
"     <li>",
"      Capillus (KP);",
"     </li>",
"     <li>",
"      Da Fei Xin (CL);",
"     </li>",
"     <li>",
"      Growell (SG);",
"     </li>",
"     <li>",
"      Hair Max (PK);",
"     </li>",
"     <li>",
"      Hair-Treat (IL);",
"     </li>",
"     <li>",
"      Hair-Treat Forte (IL);",
"     </li>",
"     <li>",
"      Hairex (IN);",
"     </li>",
"     <li>",
"      Hairgrow (HK);",
"     </li>",
"     <li>",
"      Kenacin (PY);",
"     </li>",
"     <li>",
"      Locemix (AR);",
"     </li>",
"     <li>",
"      Minodil (TH);",
"     </li>",
"     <li>",
"      Minoxi-5 (SG);",
"     </li>",
"     <li>",
"      Minoxidil Isac (PH);",
"     </li>",
"     <li>",
"      Minoximen (IT);",
"     </li>",
"     <li>",
"      Minoxiten (DO);",
"     </li>",
"     <li>",
"      Minoxyl (KP);",
"     </li>",
"     <li>",
"      Moxidil (KP);",
"     </li>",
"     <li>",
"      Neocapil (CH, CZ);",
"     </li>",
"     <li>",
"      Neoxidil (BE, IL, SG);",
"     </li>",
"     <li>",
"      Nuhair (TH);",
"     </li>",
"     <li>",
"      Pilogan (CO);",
"     </li>",
"     <li>",
"      Recrea (SE);",
"     </li>",
"     <li>",
"      Recrea Forte (NO);",
"     </li>",
"     <li>",
"      Regaine (AE, AT, BG, BH, BR, CH, CY, CZ, DK, EE, EG, GR, HK, HN, IL, IQ, IR, IT, JO, KW, LB, LY, MY, NL, OM, PL, PT, QA, RU, SA, SY, TH, TW, VE, YE);",
"     </li>",
"     <li>",
"      Regaine Extra Strength For Men (HK);",
"     </li>",
"     <li>",
"      Regaine For Men (HK);",
"     </li>",
"     <li>",
"      Regaine For Unisex (HK);",
"     </li>",
"     <li>",
"      Regaine For Women (HK);",
"     </li>",
"     <li>",
"      Regroe (PH);",
"     </li>",
"     <li>",
"      Regrou (ID);",
"     </li>",
"     <li>",
"      Regrowth (TH);",
"     </li>",
"     <li>",
"      Remox (UY);",
"     </li>",
"     <li>",
"      Rexidil (TW);",
"     </li>",
"     <li>",
"      Rogaine (AU, FI, IE, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Scalpmad (KP);",
"     </li>",
"     <li>",
"      Tricoxane (CN);",
"     </li>",
"     <li>",
"      Ylox (AR);",
"     </li>",
"     <li>",
"      Zitoxin (VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8774952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulation of hair growth is secondary to vasodilation, increased cutaneous blood flow, and stimulation of resting hair follicles.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9617 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27379=[""].join("\n");
var outline_f26_47_27379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774871\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774876\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774956\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774960\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774872\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774915\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774929\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774925\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774926\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299719\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774932\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774921\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773197\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774962\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961988\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774952\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=related_link\">",
"      Minoxidil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/26/24996?source=related_link\">",
"      Minoxidil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=related_link\">",
"      Minoxidil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/58/33699?source=related_link\">",
"      Minoxidil (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_47_27380="Lichen sclerosus in sites of friction";
var content_f26_47_27380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus developing in sites of friction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution of lichen sclerosus in sites of friction. Note the porcelain white color (arrow), telangiectasias, peripheral hyperpigmentation, and erythema (which likely signifies disease activity).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27380=[""].join("\n");
var outline_f26_47_27380=null;
var title_f26_47_27381="Double aortic arch";
var content_f26_47_27381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Double aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Double aortic arch, viewed from anterior. The right arch is usually the larger of the two arches. A ligamentum arteriosum connects the left arch to the pulmonary artery. B) A computer reconstructed image of an MR angiogram viewed from postero-superior. Dao-descending aorta, RAA-right aortic arch, LAA-left aortic arch. The star is in the center of the vascular ring, where the trachea and esophagus are encircled (not shown in this projection).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure A) Reproduced with permission from: Fyler, D, Nadas, AS. Nadas' Pediatric Cardiology, 1st ed, Hanley and Belfus, Philadelphia 1992. Copyright &copy;1992 Elsevier.",
"     <br>",
"      Figure B) Courtesy of Laureen M. Sena, MD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27381=[""].join("\n");
var outline_f26_47_27381=null;
var title_f26_47_27382="Erythema migrans Biopsy I";
var content_f26_47_27382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema migrans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy obtained from within 1 cm of the peripheral margin of an erythema migrans lesion showing endothelial cell injury with incipient fibrin deposition and regenerative alterations of the endothelium. There is luminal attenuation and a very sparse infiltrate. Similar changes are noted in the central nervous system, synovium, and myocardium in advanced Lyme disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27382=[""].join("\n");
var outline_f26_47_27382=null;
var title_f26_47_27383="Bacillary angiomatosis";
var content_f26_47_27383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous lesion of bacillary angiomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27383=[""].join("\n");
var outline_f26_47_27383=null;
var title_f26_47_27384="Causes and evaluation of gynecomastia";
var content_f26_47_27384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and evaluation of gynecomastia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Glenn D Braunstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27384/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/47/27384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia, a benign proliferation of the glandular tissue of the male breast, is caused by an increase in the ratio of estrogen to androgen activity. It may be unilateral or bilateral and is diagnosed on exam as a palpable mass of tissue at least 0.5 cm in diameter (usually underlying the nipple).",
"   </p>",
"   <p>",
"    Gynecomastia is common in infancy, adolescence, and in middle-aged to older adult males. Pseudogynecomastia, which is often seen in obese men, refers to fat deposition without glandular proliferation and does not require evaluation. Gynecomastia must be differentiated from breast carcinoma, which is far less common.",
"   </p>",
"   <p>",
"    The causes and evaluation of gynecomastia will be reviewed here. Epidemiology, pathogenesis, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link\">",
"     \"Management of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic gynecomastia, which resolves spontaneously in most cases, is common in infant and adolescent boys. In adult patients seeking help for gynecomastia, current estimates suggest the following etiologies (",
"    <a class=\"graphic graphic_table graphicRef53468 \" href=\"UTD.htm?41/21/42331\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of gynecomastia\", section on 'Prevalence'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent pubertal gynecomastia &mdash; 25 percent",
"     </li>",
"     <li>",
"      Drugs &mdash; 10 to 25 percent",
"     </li>",
"     <li>",
"      No detectable abnormality &mdash; 25 percent",
"     </li>",
"     <li>",
"      Cirrhosis or malnutrition &mdash; 8 percent",
"     </li>",
"     <li>",
"      Hypogonadism &mdash; primary (8 percent), secondary (2 percent)",
"     </li>",
"     <li>",
"      Testicular tumors &mdash; 3 percent",
"     </li>",
"     <li>",
"      Hyperthyroidism &mdash; 1.5 percent",
"     </li>",
"     <li>",
"      Chronic renal insufficiency &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies in pubertal boys with gynecomastia have found no differences in single-point measurements of serum concentrations of testosterone, estradiol, estrone, or gonadotropins from those in normal boys [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, some reports have shown a transient increase in estradiol concentration at the onset of puberty in boys who develop gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/2\">",
"     2",
"    </a>",
"    ]. These boys may also have wider fluctuations of estradiol levels, with an absolute increase in 24-hour concentration of estradiol, which may reflect increased conversion of adrenal androgens to estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Adrenal androgen secretion rises during adrenarche, which occurs independently of and before the maturation of the hypothalamic-pituitary-gonadal axis (gonadarche).",
"   </p>",
"   <p>",
"    During puberty, the serum estradiol concentrations rise to adult levels before the testosterone concentration. It is likely that this transient imbalance accounts for much of the",
"    <span class=\"nowrap\">",
"     estrogen/androgen",
"    </span>",
"    imbalance that leads to pubertal gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/5,6,8,9\">",
"     5,6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pubertal gynecomastia usually resolves spontaneously within six months to two years of onset, but in some instances, may persist after completion of puberty into adulthood, resulting in persistent pubertal gynecomastia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many drugs that have been associated with gynecomastia (",
"    <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"     table 2",
"    </a>",
"    ). The pathophysiologic mechanism for some, such as estrogens or antiandrogens, is quite clear. However, for others such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , the mechanisms are likely more complex. Spironolactone can increase the aromatization of testosterone to estradiol, decrease the testosterone production rate by the testes, and displace testosterone from SHBG, thereby increasing its metabolic clearance rate. Spironolactone also can act as an antiandrogen by binding to androgen receptors and displacing or preventing binding of testosterone and dihydrotestosterone to their receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a placebo-controlled trial of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for heart failure, endocrine side effects (gynecomastia, breast pain, impotence, and decreased libido) were seen in 10 percent compared with 3 percent in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/12\">",
"     12",
"    </a>",
"    ]. Gynecomastia will occur in almost every male who takes a large dose of spironolactone (&ge;100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    eg, to treat men with liver failure or hypertension due to aldosterone excess [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , a newer selective aldosterone antagonist, in over 6500 patients with heart failure, gynecomastia, impotence, or breast pain occurred with equal frequency in the eplerenone and placebo groups (1.0 versus 1.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For many of the drugs listed in the table, a clear-cut relationship between the drug ingestion and gynecomastia has not been established (",
"    <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"     table 2",
"    </a>",
"    ). The presumed relationship has been based upon epidemiologic studies or challenge-rechallenge studies in small numbers of individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even drugs within the same class do not all cause gynecomastia to the same extent. Among the calcium channel blockers, as an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    has the highest frequency of gynecomastia and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    the lowest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. Thus, in an older man who is at increased risk of gynecomastia simply on the basis of age, diltiazem would be preferable to nifedipine.",
"   </p>",
"   <p>",
"    Another example is the use of H2-receptor or parietal cell proton-pump blockers; the incidence of gynecomastia is highest with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    and then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    and lowest with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, omeprazole would be a better choice in an older individual with other risk factors for developing gynecomastia.",
"   </p>",
"   <p>",
"    Gynecomastia occurs in over 50 percent of men with prostate cancer receiving estrogen or antiandrogen monotherapy. Strategies for preventing or treating this common complication are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of gynecomastia\", section on 'Prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Herbal products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tea tree oil and lavender oil, plant-derived oils that are available as over-the-counter skin care products (lotions, soaps, and shampoos), have been associated with gynecomastia. This was illustrated in a report of three prepubertal boys in whom gynecomastia developed after repeated use of skin products containing the oils [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/17\">",
"     17",
"    </a>",
"    ]. Both oils had weak estrogenic and antiandrogenic properties in in vitro studies, and the gynecomastia resolved when the skin products were discontinued. Although the prevalence of this complication in the population is unknown, we suggest that regular exposure to these products should be avoided.",
"   </p>",
"   <p>",
"    Other environmental substances with estrogenic or antiandrogenic properties have also been reported to cause gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Soy protein formulas, which contain high concentrations of phytoestrogens, were not associated with gynecomastia in one study in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast enlargement that is seen in men with HIV receiving highly active antiretroviral therapy (HAART) is usually due to fat tissue (lipomastia or pseudogynecomastia) as part of a fat redistribution syndrome (lipodystrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/22\">",
"     22",
"    </a>",
"    ]. However, cases of true gynecomastia have also been described, thought to be due to coexisting hypogonadism or possible estrogen-like effects of some drugs, in particular,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia in adults is often multifactorial. Aging per se is associated with an increase in body fat relative to the lean body mass. Adipose tissue is an active site of extraglandular aromatization of testosterone to estradiol and of androstenedione to estrone. In addition, there tends to be a gradual decrease in testosterone production by the aging testes and an increase in SHBG levels, resulting in a fall in the free testosterone concentration with a reciprocal increase in the luteinizing hormone (LH) level [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These two factors probably account for most patients who have \"idiopathic\" gynecomastia. Older men are also more likely to take medications associated with gynecomastia than are younger men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cirrhosis or malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of gynecomastia in cirrhotic patients is as high as 67 percent; however, this may not be significantly different from control patients drawn from the same population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Cirrhosis is accompanied by several changes that probably explain the development of gynecomastia: an increased production rate of androstenedione from the adrenals, enhanced aromatization of androstenedione to estrone, and increased conversion of estrone to estradiol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/28\">",
"     28",
"    </a>",
"    ]. Additionally, many patients receive high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , which can contribute to the pathogenesis of gynecomastia in this population.",
"   </p>",
"   <p>",
"    Several studies were carried out on American prisoners of war who were freed at the end of World War II. About 10 percent had developed gynecomastia during starvation, while between 5 and 50 percent noted breast tenderness, pain, and enlargement within two to three months of refeeding after release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/29\">",
"     29",
"    </a>",
"    ]. Prior to refeeding, approximately 80 percent reported impotence, 85 percent had decreased libido, and 73 percent showed testicular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During starvation, both gonadotropin and testosterone levels were probably reduced, while estrogen production was probably normal due to normal estrogen production from adrenal precursors. These changes will promote the development of gynecomastia. During refeeding, gonadotropins rise, resulting in both an increase in testosterone secretion and a marked elevation in estradiol production that mimics normal puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, patients who develop refeeding gynecomastia may be said to have undergone a \"second puberty.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Male hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypogonadism can be due to a congenital abnormality such as Klinefelter's syndrome or an enzymatic defect in the testosterone biosynthetic pathway, or to testicular trauma, infection, infiltrative disorders, vascular insufficiency or aging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    .) The associated reduction in testosterone production leads to a decrease in the serum testosterone concentration and a compensatory rise in LH release. The excess LH results in enhanced Leydig cell stimulation with inhibition of the 17,20-lyase and 17-hydroxylase activities and increased aromatization of testosterone to estradiol; the net effect is an increase in estradiol relative to testosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary hypogonadism due to a hypothalamic or pituitary abnormality may also be associated with gynecomastia. In these patients, the production of LH is deficient, resulting in a low testosterone production rate and low estradiol production from the testes. However, the adrenal cortex continues to produce estrogen precursors that are aromatized in extraglandular tissue; the result is an",
"    <span class=\"nowrap\">",
"     estrogen/androgen",
"    </span>",
"    imbalance.",
"   </p>",
"   <p>",
"    Men with hyperprolactinemia may develop gynecomastia due to prolactin's effect on reducing the secretion of gonadotropins leading to secondary hypogonadism. Prolactin itself will stimulate milk production in breast tissue that has been primed by estrogen and progesterone, but does not directly cause gynecomastia itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Testicular neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell tumors account for approximately 95 percent of testicular neoplasms; between 2.5 percent and 6 percent of affected patients have gynecomastia at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/31\">",
"     31",
"    </a>",
"    ]. The gynecomastia is associated with secretion of human chorionic gonadotropin (hCG) by foci of choriocarcinoma or trophoblastic cells in the tumor (",
"    <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high levels of hCG lead to Leydig cell dysfunction through inhibition of the cytochrome P450c17 enzyme, which mediates the 17,20-lyase and 17-hydroxylase activities in the testes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/32\">",
"     32",
"    </a>",
"    ]. hCG also stimulates interstitial (Leydig) cell aromatase activity, which converts androgen precursors to estrone and estradiol. The net effect is a relative increase in estradiol to testosterone production.",
"   </p>",
"   <p>",
"    Gynecomastia is a poor prognostic sign if present at the time of diagnosis of the tumor. It also occurs in about 15 percent of patients after successful treatment with surgery, chemotherapy, or radiation therapy; at this time, it does not affect predicted survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This form of gynecomastia results from hypogonadism secondary to the chemotherapy or radiation; hCG is not found in the serum. It often spontaneously resolves within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gynecomastia is also found in 20 to 30 percent of patients with the less common (2 percent of all testicular tumors) Leydig cell tumors of the testes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/35\">",
"     35",
"    </a>",
"    ]. These tumors are found in 6- to 10-year-old boys who present with precocious puberty, and in 26- to 35-year-old men who present with a testicular mass, gynecomastia, impotence, and loss of libido. Approximately 10 percent of these tumors are malignant. The Leydig cell tumors secrete increased quantities of estradiol and also aromatize more androgen precursors to estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In adults, testosterone production is decreased because the increased estradiol levels inhibit gonadotropin secretion, which in turn leads to secondary hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large cell calcifying Sertoli cell (sex-cord) tumors of the testes are associated with gynecomastia and feminization through excessive aromatase activity, converting androstenedione to estrone and testosterone to estradiol. These tumors may occur sporadically or as manifestations of two autosomal dominant disorders: Peutz-Jeghers syndrome and the Carney complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia has been reported in as many as 25 to 40 percent of men with hyperthyroidism due to Graves' disease, although one study suggests that the actual prevalence is less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Serum LH levels are often elevated, contributing to increased estradiol relative to testosterone production by Leydig cells. There is also enhanced aromatization of testosterone to estradiol and of androstenedione to estrone in extraglandular tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/42\">",
"     42",
"    </a>",
"    ]. This results in increased concentration of SHBG. Free testosterone levels are normal or low, while free estradiol levels are elevated. Thus, gynecomastia results from the combination of decreased free androgen levels combined with the overproduction of estrogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia occurs in about 50 percent of patients treated with maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/43\">",
"     43",
"    </a>",
"    ]. The primary cause of the gynecomastia appears to be Leydig cell dysfunction. Serum testosterone levels are low and gonadotropins are appropriately elevated; the metabolic clearance of LH is also reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/44\">",
"     44",
"    </a>",
"    ]. Gynecomastia may occur following renal transplantation as gonadal function improves (\"refeeding gynecomastia\")",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of transplantation medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other rare causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Feminizing adrenocortical tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are rare tumors that are malignant in approximately 75 percent of cases, with a median survival of 1.5 years. In a series of 52 patients, 98 percent had gynecomastia, 58 percent had a palpable tumor, and approximately 50 percent had testicular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/45\">",
"     45",
"    </a>",
"    ]. Serum levels of dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, and estradiol are increased, while total and free testosterone levels are reduced. Urinary 17-ketosteroid excretion is generally markedly elevated. Gonadotropin levels are usually normal or low. The combination of increased secretion of estrogens by the tumor and increased peripheral aromatization of adrenal androgens to estrogens accounts for the gynecomastia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ectopic hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum levels of immunoreactive hCG are found in approximately 18 percent of patients with a wide variety of nontrophoblastic neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/46\">",
"     46",
"    </a>",
"    ]. The levels of hCG are generally only modestly raised and most patients do not exhibit clinical evidence of excess hCG production, in part because the majority of patients have production of the biologically inactive free beta subunit of hCG rather than the biologically active intact molecule. There are, however, a few exceptions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precocious puberty can occur in boys with hCG-secreting hepatoblastomas [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, large cell carcinoma of the lung, gastric carcinoma, renal cell carcinoma, and occasionally hepatoma have been associated with gynecomastia and marked elevations of serum hCG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of the gynecomastia is similar to that found with hCG-secreting germ cell neoplasms of the testes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     True hermaphroditism",
"    </span>",
"    &nbsp;&mdash;&nbsp;True hermaphrodites harbor both testicular and ovarian tissue and may develop gynecomastia from excessive estrogen secretion by the ovarian component [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, the increased estrogen production can suppress intratesticular P450c17 activity as well as LH secretion, thereby reducing testosterone production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Androgen insensitivity syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The androgen insensitivity syndromes are a group of disorders due to defects in or absence of the intracellular androgen receptor in androgen target tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/48\">",
"     48",
"    </a>",
"    ]. The clinical manifestations are variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One end of the spectrum is complete androgen insensitivity (associated with complete absence of the androgen receptor and formerly called testicular feminization), with absence of pubic and axillary hair, absence of the uterus, fallopian tubes and upper third of the vagina, non-fused labial-scrotal folds, and breasts that resemble those of a normal woman. These genotypic males appear to be phenotypic females; they have a perineal urethra and open labia rather than a penile urethra and scrotum. Because they are phenotypic women, these patients have \"gynecomastia\" only in a technical sense.",
"      <br/>",
"      <br/>",
"      In complete androgen insensitivity, LH levels rise at the time of expected puberty and stimulate the functionally normal testes to secrete testosterone and estradiol. Because of the androgen insensitivity, the LH levels tend to increase above normal, which leads to excess stimulation of the Leydig cells and an increased secretion of both androgens and estrogens. The elevated serum testosterone is also aromatized into estradiol. The net effect is an increased serum concentration of estrogens with lack of androgen activity, leading to breast growth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the other end of the spectrum are phenotypic males who develop gynecomastia as the only manifestation of a partial androgen receptor defect, most often a point-mutation in the receptor gene [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Aromatase excess syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial prepubertal gynecomastia is a rare disorder of increased aromatase activity resulting in severe estrogen excess. The disorder appears to be due to heterozygous inversions or polymorphisms of the p450 aromatase gene (CYP19) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. The mode of inheritance appears to be autosomal dominant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/52,54\">",
"     52,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial description was of an eight-year-old boy who had accelerated growth and bone maturation and severe feminization with gynecomastia due to a 50-fold increase in extraglandular conversion of plasma androstenedione to estrone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/50\">",
"     50",
"    </a>",
"    ]. This child's heterosexual precocity was felt to be due to a failure of fetal aromatase activities to regress following birth.",
"   </p>",
"   <p>",
"    It is possible that some patients with the diagnosis of \"idiopathic\" gynecomastia actually represent excessive extraglandular aromatase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aromatase inhibitors, which have had limited success in the treatment of other causes of gynecomastia, may be effective in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia may be distinguished from pseudogynecomastia (which is due to an increase in breast fat, but not glandular tissues), by having the patient lie on his back with his hands behind his head. The examiner then places his or her thumb and forefinger on each side of the breast and slowly brings them together (",
"    <a class=\"graphic graphic_figure graphicRef72334 \" href=\"UTD.htm?19/17/19730\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In true gynecomastia, a ridge of glandular tissue will be felt that is reasonably symmetrical to the nipple-areolar complex.",
"     </li>",
"     <li>",
"      In pseudogynecomastia, the fingers will not meet any resistance until they reach the nipple.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gynecomastia can usually be detected when the size of the glandular tissue exceeds 0.5 cm in diameter.",
"   </p>",
"   <p>",
"    In addition, gynecomastia needs to be differentiated from other causes of breast masses, in particular, breast cancer. The latter is typically eccentric to the nipple-areolar complex, firm to hard in texture, and may be associated with skin dimpling, nipple discharge, and regional lymphadenopathy. If the differentiation cannot be made by physical examination, mammography should be done.",
"   </p>",
"   <p>",
"    The combination of a careful history and physical examination and a few diagnostic tests can result in the identification of the cause of gynecomastia in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is an adolescent and has a normal general physical and genital examination, then it is quite likely that he has pubertal gynecomastia. Reevaluation at six monthly intervals will show whether the condition is persistent or not; improvement supports the initial impression of a pubertal cause.",
"     </li>",
"     <li>",
"      The patient should be asked about the ingestion of any of the drugs that can cause gynecomastia (",
"      <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"       table 2",
"      </a>",
"      ). Improvement in gynecomastia after discontinuance or substitution of one of these drugs for one to several months strongly suggests that the drug was responsible.",
"     </li>",
"     <li>",
"      Symptoms and signs of liver and kidney disease should be sought, as should those of hyperthyroidism (eg, weight loss, tachycardia, goiter, tremor, or exophthalmos). The patient should also be closely evaluated for signs and symptoms that suggest hypogonadism (eg, impotence, decreased libido and strength, and change in testicular size).",
"     </li>",
"     <li>",
"      An abdominal mass might suggest adrenocortical carcinoma, and a testicular mass or change in testicular size or consistency might indicate a neoplasm. If any of these conditions are found, it is the likely cause of the gynecomastia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the gynecomastia is of",
"    <strong>",
"     recent onset",
"    </strong>",
"    or is",
"    <strong>",
"     painful or tender",
"    </strong>",
"    , then serum concentrations of hCG, LH, testosterone, and estradiol should be measured unless the cause is clearly apparent after the above clinical evaluation. Diagnostic tests for asymptomatic gynecomastia discovered during a physical examination in a patient without one of the underlying pathologic conditions noted above and who is not ingesting one of the drugs shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"     table 2",
"    </a>",
"    ) have a low yield. However, because of the relatively common finding of hypogonadism in aging males, measurement of a morning testosterone level is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/55\">",
"     55",
"    </a>",
"    ]. If it is low, then free or bioavailable testosterone and luteinizing hormone levels should be measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The figure provides an algorithm for interpreting the results of the hormone studies with further recommendations for additional testing based upon the initial results (",
"    <a class=\"graphic graphic_figure graphicRef57959 \" href=\"UTD.htm?25/46/26351\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=see_link\">",
"       \"Patient information: When men develop breasts (gynecomastia) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=see_link\">",
"       \"Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic gynecomastia, which resolves spontaneously in most cases, is common in infant and adolescent boys. In adult patients seeking help for gynecomastia, current estimates suggest the following etiologies (",
"    <a class=\"graphic graphic_table graphicRef53468 \" href=\"UTD.htm?41/21/42331\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27384/abstract/56\">",
"     56",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of gynecomastia\", section on 'Prevalence'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent pubertal gynecomastia &mdash; 25 percent (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Puberty'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Drugs &mdash; 10 to 25 percent (",
"      <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"       table 2",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H4\">",
"       'Drugs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      No detectable abnormality &mdash; 25 percent (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Idiopathic'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cirrhosis or malnutrition &mdash; 8 percent (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cirrhosis or malnutrition'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Male hypogonadism &mdash; primary (8 percent), secondary (2 percent) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Male hypogonadism'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Testicular tumors &mdash; 3 percent (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Testicular neoplasms'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hyperthyroidism &mdash; 1.5 percent (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Hyperthyroidism'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chronic renal insufficiency &mdash; 1 percent (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Chronic renal failure'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a careful history and physical examination and a few diagnostic tests can result in the identification of the cause of gynecomastia in the majority of patients.",
"   </p>",
"   <p>",
"    In adolescent boys, breast enlargement is almost always due to pubertal gynecomastia, which resolves spontaneously in most cases.",
"   </p>",
"   <p>",
"    Adults should be asked about the ingestion of any of the drugs that can cause gynecomastia. Symptoms and signs of hypogonadism, hyperthyroidism, or liver and kidney disease should be sought.",
"   </p>",
"   <p>",
"    Laboratory evaluation (serum hCG, LH, testosterone, and estradiol) is performed if the gynecomastia is of recent onset or painful, unless the cause is clearly apparent after the above clinical evaluation. On the other hand, asymptomatic gynecomastia that is discovered during a physical examination in a patient who does not have one of the underlying pathologic conditions noted above and who is not ingesting one of the drugs known to cause gynecomastia may not require further tests, other than a serum testosterone level to screen for hypogonadism (",
"    <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/1\">",
"      Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/2\">",
"      Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975; 86:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/3\">",
"      Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr 1979; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/4\">",
"      Knorr D, Bidlingmaier F. Gynaecomastia in male adolescents. Clin Endocrinol Metab 1975; 4:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/5\">",
"      Bidlingmaier F, Knorr D. Plasma testosterone and estrogens in pubertal gynecomastia. Z Kinderheilkd 1973; 115:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/6\">",
"      Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/7\">",
"      Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia. Clin Endocrinol (Oxf) 1979; 11:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/8\">",
"      Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979; 48:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/9\">",
"      LaFranchi SH, Parlow AF, Lippe BM, et al. Pubertal gynecomastia and transient elevation of serum estradiol level. Am J Dis Child 1975; 129:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/10\">",
"      Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/11\">",
"      Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/12\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/13\">",
"      Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/14\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/15\">",
"      Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988; 148:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/16\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/17\">",
"      Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/18\">",
"      Finkelstein JS, McCully WF, MacLaughlin DT, et al. The mortician's mystery. Gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer. N Engl J Med 1988; 318:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/19\">",
"      Brody SA, Loriaux DL. Epidemic of gynecomastia among haitian refugees: exposure to an environmental antiandrogen. Endocr Pract 2003; 9:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/20\">",
"      Braunstein GD. Environmental gynecomastia. Endocr Pract 2008; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/21\">",
"      Giampietro PG, Bruno G, Furcolo G, et al. Soy protein formulas in children: no hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 2004; 17:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/22\">",
"      Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read 2005; 15:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/23\">",
"      Jover F, Cuadrado JM, Roig P, et al. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004; 10:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/24\">",
"      Smals AG. Gynaecomastia. Neth J Med 1987; 31:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/25\">",
"      Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993; 159:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/26\">",
"      Edmondson, HA, Glass, SJ, Soll, SN. Gynecomastia associated with cirrhosis of the liver. Proc Soc Exp Biol Med 1939; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/27\">",
"      Cavanaugh J, Niewoehner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med 1990; 150:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/28\">",
"      Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 1975; 40:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/29\">",
"      JACOBS EC. Gynecomastia following severe starvation. Ann Intern Med 1948; 28:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/30\">",
"      Smith SR, Chhetri MK, Johanson J, et al. The pituitary-gonadal axis in men with protein-calorie malnutrition. J Clin Endocrinol Metab 1975; 41:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/31\">",
"      Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985; 56:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/32\">",
"      Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab 1979; 49:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/33\">",
"      Turner AR, Morrish DW, Berry J, MacDonald RN. Gynecomastia after cytotoxic therapy for metastatic testicular cancer. Arch Intern Med 1982; 142:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/34\">",
"      Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/35\">",
"      Bercovici JP, Tater D, Khoury S, et al. Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor. J Clin Endocrinol Metab 1981; 53:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/36\">",
"      Bercovici JP, Nahoul K, Ducasse M, et al. Leydig cell tumor with gynecomastia: further studies--the recovery after unilateral orchidectomy. J Clin Endocrinol Metab 1985; 61:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/37\">",
"      Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/38\">",
"      Chopra IJ, Tulchinsky D. Status of estrogen-androgen balance in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab 1974; 38:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/39\">",
"      Ashkar FS, Smoak WM 3rd, Gilson AJ, Miller R. Gynecomastia and mastoplasia in Graves' disease. Metabolism 1970; 19:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/40\">",
"      Chan WB, Yeung VT, Chow CC, et al. Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad Med J 1999; 75:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/41\">",
"      Bercovici JP, Mauvais-Jarvis P. Hyperthyroidism and gynecomastia: metabolic studies. J Clin Endocrinol Metab 1972; 35:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/42\">",
"      Olivo J, Gordon GG, Rafii F, Southren AL. Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver. Steroids 1975; 26:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/43\">",
"      Freeman RM, Lawton RL, Fearing MO. Gynecomastia: an endocrinologic complication of hemodialysis. Ann Intern Med 1968; 69:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/44\">",
"      Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/45\">",
"      GABRILOVE JL, SHARMA DC, WOTIZ HH, DORFMAN RI. FEMINIZING ADRENOCORTICAL TUMORS IN THE MALE. A REVIEW OF 52 CASES INCLUDING A CASE REPORT. Medicine (Baltimore) 1965; 44:37.",
"     </a>",
"    </li>",
"    <li>",
"     Braunstein GD. Placental proteins as tumor markers. In: Immunodiagnosis of cancer, Herberman RB, Mercer DW (Eds), Marcel Dekker, New York 1990. p.673.",
"    </li>",
"    <li>",
"     van Niekerk WA. True hermaphroditism. In: The Intersex Child, Josso N (Ed), S Karger AG, Basel, Switzerland 1981. p.80.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/48\">",
"      Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/49\">",
"      Rochefort H, Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 1983; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/50\">",
"      Hemsell DL, Edman CD, Marks JF, et al. Massive extranglandular aromatization of plasma androstenedione resulting in feminization of a prepubertal boy. J Clin Invest 1977; 60:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/51\">",
"      Berkovitz GD, Guerami A, Brown TR, et al. Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids. J Clin Invest 1985; 75:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/52\">",
"      Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998; 83:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/53\">",
"      Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/54\">",
"      Binder G, Iliev DI, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/55\">",
"      Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27384/abstract/56\">",
"      Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7476 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-8FDE9D9275-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27384=[""].join("\n");
var outline_f26_47_27384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Herbal products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cirrhosis or malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Testicular neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other rare causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Feminizing adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ectopic hCG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - True hermaphroditism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Androgen insensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Aromatase excess syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7476|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/17/19730\" title=\"figure 1\">",
"      Exam for gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/46/26351\" title=\"figure 2\">",
"      Evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/21/42331\" title=\"table 1\">",
"      Causes of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/35/21053\" title=\"table 2\">",
"      Drugs and gynecomastia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=related_link\">",
"      Management of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=related_link\">",
"      Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=related_link\">",
"      Patient information: When men develop breasts (gynecomastia) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_47_27385="Cardiac injury from blunt trauma";
var content_f26_47_27385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac injury from blunt trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Eric Legome, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Howard Kadish, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27385/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/47/27385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt cardiac injury (BCI) encompasses a spectrum of pathology ranging from clinically silent, transient arrhythmias to deadly cardiac wall rupture. The most common form is \"cardiac contusion\" (ie, injury to the myocardium), which remains the subject of considerable debate. The absence of a clear definition and accepted gold standard for testing makes the diagnosis of cardiac contusion difficult. Important considerations in blunt cardiac trauma include arrhythmia, cardiac wall motion abnormalities, possibly progressing to cardiogenic shock, and rupture of valves, the septum, or a ventricular, atrial, or septal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and management of cardiac injuries sustained in adults from blunt thoracic trauma will be reviewed here. Other injuries from blunt trauma and injuries in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, DEFINITIONS, AND SCORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of BCI is unknown, and estimates vary widely. Of diagnosed BCIs, \"myocardial contusion\" or \"cardiac contusion\" is most common. However, each of these terms has been used to refer to a range of cardiac injuries. The absence of clear diagnostic criteria and reliable diagnostic tests makes reporting difficult. Suggestive symptoms may be unrelated to BCI, while some injuries may be clinically asymptomatic. Furthermore, some criteria used to define significant BCI, such as arrhythmias, may be due to the effects of multiple trauma in a susceptible patient (eg, patient with preexisting heart disease). Other diagnostic criteria, such as an elevated troponin, may be seen in major trauma remote from the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiac biomarkers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Due to the ambiguity surrounding the terms \"myocardial contusion\" and \"cardiac contusion\", we prefer to describe BCIs in terms of specific injuries (eg, septal rupture, myocardial infarction) or cardiac dysfunction (eg, diminished contractility in the absence of arrhythmia or hemorrhage). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Types of injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cardiac rupture is the most devastating BCI. Most patients who sustain rupture of a heart chamber do not reach the emergency department alive. Chamber rupture is described primarily in autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy and mechanism of injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While not widely used in emergency medicine, the cardiac injury scale developed by the American Association for Surgery of Trauma is easy to use, applies to both blunt and penetrating cardiac injuries, and provides a standard scheme for research purposes and documentation (",
"    <a class=\"graphic graphic_table graphicRef75627 \" href=\"UTD.htm?26/21/26972\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY AND MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt cardiac injury (BCI) occurs most often from motor vehicle collisions (MVC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/7\">",
"     7",
"    </a>",
"    ]. Falls and crush injuries cause a smaller number. Commotio Cordis, a rare type of BCI in which low impact chest trauma causes sudden cardiac arrest, usually occurs from being struck by a projectile during sports. Arrest appears to stem from the timing of the blow during a period of electrical susceptibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H10#H10\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Commotio cordis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid deceleration is the mechanism responsible for most BCIs. A direct blow to the precordium also accounts for a sizable number of cases. Any patient involved in a MVC with sudden deceleration, or who sustains significant chest trauma or severe multiple trauma is at risk.",
"   </p>",
"   <p>",
"    Several forces may be involved in BCI, including compression of the heart between the spine and sternum, abrupt pressure fluctuations in the chest and abdomen, shearing from rapid deceleration, and blast injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. In addition, fragments from rib fractures can directly traumatize the heart.",
"   </p>",
"   <p>",
"    The right heart is most commonly injured. This is probably due to its position closest to the anterior chest wall. High pressure ventricular injuries appear to be as common as low pressure atrial injuries, but findings vary based on the type of study (ie, clinical or autopsy). In autopsy series, ventricular injuries predominate. Other pathological findings include valvular tear or rupture, septal tears, and coronary artery thrombosis or laceration, but these are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREHOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital management depends upon patient symptoms and severity of illness. Prehospital providers should treat patients with possible severe cardiac injury according to the principles of Advanced Trauma Life Support&reg;, paying special attention to the patient's airway, breathing, and circulation. Rapid transport to the closest trauma center is crucial; interventions causing unnecessary delay must be avoided. A detailed discussion of prehospital trauma care is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of BCI in the field can be difficult. Trauma patients may have multiple injuries and signs suggestive of BCI, such as arrhythmia, which may stem from hypotension, acidosis, or preexisting heart disease. For patients with minor injuries and no respiratory difficulty, chest pain, or other concerning symptoms, no intervention may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of BCI can vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/1\">",
"     1",
"    </a>",
"    ]. Concomitant injuries often affect presentation, and it may be difficult to determine whether symptoms stem primarily from the cardiac injury. Mortality from major structural injuries, such as chamber rupture or perforation, is high and most such patients die in the field. The basic types of BCI are described below; diagnostic approach and management are addressed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic approach'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Types of injury",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Myocardial rupture",
"      </strong>",
"      &ndash; Nonspecific signs and concomitant injuries make clinical diagnosis of myocardial injury difficult. Signs such as hypotension associated with distended neck veins and muffled heart sounds suggest pericardial tamponade (ie, contained myocardial tear or rupture), which may occur with BCI. However, such signs may not be present (eg, patient with hemorrhage and hypotension may not have distended neck veins). Immediate bedside ultrasound may reveal the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiogram'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Most patients with severe BCI, such as uncontained myocardial rupture, do not reach the emergency department (ED) alive [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Of those who do, hypotension may reduce pressure on the injured myocardium, which may then worsen as fluid resuscitation restores blood pressure. In a minority of patients, rapid diagnosis by echocardiography or CT scan and operative intervention can be lifesaving [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/12\">",
"       12",
"      </a>",
"      ]. Less severe injuries to the ventricular wall may lead to delayed necrosis and manifest as delayed rupture within several days of admission.",
"      <br/>",
"      <br/>",
"      Atrial rupture occurs far less often than ventricular rupture (most likely due to the location of the atria and their lower compliance) and presentation may be delayed and less acute [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/13\">",
"       13",
"      </a>",
"      ]. Right atrial rupture is seen in about 10 percent of wall ruptures from blunt trauma, and left atrial rupture less often.",
"     </li>",
"     <li>",
"      <strong>",
"       Septal and valvular injury",
"      </strong>",
"      &ndash; Septal injury appears to be rare and its presentation variable. Septal injury may involve insignificant tears or frank rupture, and may occur in isolation or with valvular injury. Findings may include acute valvular insufficiency with widened pulse pressure and signs of acute heart failure.",
"      <br/>",
"      <br/>",
"      Isolated valvular injury is likewise rare [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/9,14,15\">",
"       9,14,15",
"      </a>",
"      ]. The aortic valve is most often injured, followed by the mitral and tricuspid valves. The lesion may consist of a tear of the leaflet or a partial or full thickness tear of the papillary muscle or chordae tendineae. Presentation may vary, in part depending upon the lesion, but falls somewhere on the spectrum of acute valvular insufficiency with right or left sided heart failure and a new cardiac murmur. A widened pulse pressure may be present with aortic valvular injury. Treatment for septal and valvular injury is generally surgical and timing depends upon the presenting signs and acuity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One retrospective review found a significant increase in tricuspid and aortic valve insufficiency, incompetence, and regurgitation among patients with a history of BCI. Milder cases may go undiagnosed initially and present late with heart failure from long-standing valvular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/18\">",
"       18",
"      </a>",
"      ]. While less common, mitral valve insufficiency has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/15,19\">",
"       15,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Myocardial infarction",
"      </strong>",
"      &ndash; Myocardial infarction (MI) is a rare complication of BCI reported in victims of motor vehicle collisions and minor trauma. Causes include coronary artery dissection, laceration, and thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/20-27\">",
"       20-27",
"      </a>",
"      ]. The left anterior descending artery appears to be involved most often [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/28\">",
"       28",
"      </a>",
"      ]. An electrocardiogram (ECG) should be obtained early in the evaluation of any patient with significant blunt thoracic trauma to screen for cardiac dysfunction secondary to blunt injury and to rule out the rare MI. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocardiogram'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic approach'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac dysfunction",
"      </strong>",
"      &ndash; The lack of a clear definition for myocardial contusion is problematic, and we prefer the term cardiac dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology, definitions, and scoring'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The exact incidence of BCI with cardiac dysfunction (eg, decreased contractility) is unknown. The cause of such dysfunction can be difficult to determine in the multiply injured patient with many reasons for hypotension. An echocardiogram is useful in trauma patients with signs of cardiac dysfunction to diagnose the cause and assist with management. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiogram'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In animal studies, cardiac dysfunction from blunt trauma often manifests multiple hemodynamic derangements unrelated to arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Potential derangements include diminished contractility, decreased cardiac and stroke volume indices, and low mean arterial pressure. Myocardial metabolism may be impaired, as reflected by decreases in oxygen consumption and lactate extraction, and right-sided cardiac pressures may increase. Many of these changes resolve in less than a day.",
"     </li>",
"     <li>",
"      <strong>",
"       Arrhythmia",
"      </strong>",
"      &ndash; Clinicians should assume that hemorrhage is the cause of tachycardia in the trauma patient until proven otherwise. Once hemorrhage is ruled out, findings such as unexplained, persistent tachycardia, new bundle branch block, and minor arrhythmia (eg, occasional premature ventricular contractions) raise concern for BCI. Patients with any of these findings should be admitted for cardiac monitoring. Case reports describe a wide range of arrhythmias associated with BCI, including supraventricular tachycardia (eg, atrial fibrillation) and ventricular fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Few patients with BCI develop an arrhythmia that requires treatment. While diagnostic criteria vary, making the number difficult to determine, the range often cited is 0 to 5 percent among patients with BCI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. Criteria may involve elevated cardiac biomarkers, an abnormal ECG or echocardiogram, or some combination of these. Most patients admitted for monitoring manifest minor arrhythmias.",
"     </li>",
"     <li>",
"      <strong>",
"       Concomitant injury and sternal fracture",
"      </strong>",
"      &ndash; BCI often presents with concomitant injuries. These can include injuries to the head, thorax, abdomen, and spine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In one autopsy series, sternal fractures were found in 76 percent of cases involving cardiac injury, but only 18 percent of deaths without BCI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/5\">",
"       5",
"      </a>",
"      ]. Nevertheless, a sternal fracture does not necessarily imply the presence of BCI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/36-40\">",
"       36-40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2505321\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2505328\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;While blunt cardiac injury (BCI) is often associated with thoracic trauma, it can occur in any patient with multisystem trauma. Initial evaluation proceeds according to standard Advanced Trauma Life Support&reg; protocols, beginning with stabilization of the patient's airway, breathing, and circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should assume that",
"    <strong>",
"    </strong>",
"    hypotension in the trauma patient stems from",
"    <strong>",
"     hemorrhage",
"    </strong>",
"    ,",
"    <strong>",
"     not",
"    </strong>",
"    <strong>",
"     cardiac dysfunction",
"    </strong>",
"    , until proven otherwise. With hypotension in the setting of isolated chest trauma, clinicians should look for pericardial tamponade or a tension pneumothorax in addition to hemorrhage. Evaluation and initial management of the patient with thoracic trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is an important screening test for hemodynamically stable patients with potential BCI. An ECG consistent with BCI may reveal persistent sinus tachycardia, another arrhythmia, a new bundle branch block, or ST depressions or elevations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It can be difficult to determine whether the abnormality is a primary event (eg, an acute coronary syndrome that preceded trauma), a direct result of cardiac injury, or a problem brought on by the physiologic stress of severe trauma.",
"   </p>",
"   <p>",
"    One large, retrospective study found that patients diagnosed with BCI have two to four times the baseline risk of arrhythmia, depending upon the patient's age, compared with matched controls who sustain blunt thoracic trauma without BCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/43\">",
"     43",
"    </a>",
"    ]. Although the study has significant methodologic limitations, it notes the incidence of arrhythmia other than sinus tachycardia (ST) to be &lt;1 percent, and the most common arrhythmia other than ST to be atrial fibrillation. ECG abnormalities, such as ST changes and bundle branch blocks, are not discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can provide important information in the patient who manifests signs consistent with significant BCI, but contributes little to the management of hemodynamically stable patients without arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/8,44-46\">",
"     8,44-46",
"    </a>",
"    ]. We obtain an echocardiogram in any patient with blunt thoracic trauma and unexplained, persistent shock out of proportion to apparent injuries or despite aggressive resuscitation, and in any patient with signs consistent with significant BCI. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Focused assessment with sonography for trauma (FAST) provides the preferred initial approach for sonographic evaluation. It enables trained clinicians to determine the presence of pericardial effusion and pneumothorax rapidly and accurately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link&amp;anchor=H30174462#H30174462\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\", section on 'Pericardial examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once pericardial tamponade is ruled out, an echocardiogram is useful in trauma patients with signs of cardiac dysfunction to diagnose the cause of dysfunction, estimate the need for volume resuscitation or inotropic support, and identify other injuries requiring intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/2,8,47\">",
"     2,8,47",
"    </a>",
"    ]. Suggestive signs include abnormal cardiac wall motion and decreased cardiac contractility. Such findings may predate the current trauma in patients with chronic heart disease. Nevertheless, any abnormality should be investigated with a formal comprehensive echocardiogram performed by skilled clinicians to define wall motion abnormalities, identify thrombus, and to identify valvular rupture or dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A transesophageal echocardiogram (TEE) is superior to transthoracic echocardiography for investigating the cause of persistent hemodynamic instability or other problems thought to be related to BCI. TEE provides a clear view of wall motion abnormalities and valvular and septal injuries. While its benefits are tempered by increased invasiveness, TEE improves sensitivity for injuries that require intervention.",
"   </p>",
"   <p>",
"    In one prospective study where patients with \"severe chest injuries\" underwent both TEE and transthoracic echocardiography (TTE), TEE provided optimal images in approximately 98 percent of patients compared with 60 percent for TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/49\">",
"     49",
"    </a>",
"    ]. Moreover, multiple serious injuries including wall and valvular ruptures were not visible on TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cardiac biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of cardiac biomarkers in the setting of BCI remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. There are several reasons for this including the lack of a gold standard for BCI, highly variable clinical outcomes, and the use of different biomarkers. In the rare case of the blunt thoracic trauma patient with evidence of myocardial infarction on ECG, serial biomarkers should be measured and consultation with both cardiology and cardiac surgery urgently obtained.",
"   </p>",
"   <p>",
"    The use of cardiac biomarkers may not affect the management of blunt trauma patients with hemodynamic instability or an abnormal ECG that does not demonstrate myocardial infarction. Such patients generally undergo echocardiography and are admitted for further evaluation.",
"   </p>",
"   <p>",
"    In one prospective study of 187 patients with blunt chest trauma, an increased troponin at admission or within six hours of arrival correlated with increasing risk of arrhythmia and decreased ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/52\">",
"     52",
"    </a>",
"    ]. In another prospective study, no adverse outcomes occurred in a subgroup of 16 patients with some initial ECG abnormality but no elevation in troponin at four to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/50\">",
"     50",
"    </a>",
"    ]. While these studies are limited, they suggest that troponin measurements may be useful in the patient with ECG abnormalities. However, with a markedly abnormal ECG or complex arrhythmia, it is doubtful a negative troponin provides reassurance that further complications will not occur, and such patients should be admitted for further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/8,50,53\">",
"     8,50,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of hemodynamic instability, signs of severe injury, or an abnormal ECG, several observational studies suggest that an elevated CK-MB or cardiac troponin is nonspecific for the presence of a clinically significant BCI and has little prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/50,52,54,55\">",
"     50,52,54,55",
"    </a>",
"    ]. Moreover, abnormally elevated troponins occur more frequently among patients with significant nonthoracic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/3\">",
"     3",
"    </a>",
"    ]. This latter finding may stem from catecholamine-induced stress, hypovolemic shock with reperfusion injury, oxidative injury, bacterial or viral toxins, or microcirculatory dysfunction.",
"   </p>",
"   <p>",
"    For these reasons, we do not routinely obtain cardiac biomarkers in patients without hemodynamic instability, signs of severe injury, or an ECG with significant abnormalities. Concerning ECG abnormalities include arrhythmias other than mild sinus tachycardia, a new conduction block, and ST or T wave abnormalities suggestive of ischemia. In place of biomarkers, we use repeat examinations, serial ECGs, and cardiac monitoring during a brief course of observation (four to six hours) to screen for BCI, if concern exists. The use of biomarkers has not been shown to be more accurate than this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. While some studies suggest that biomarkers are sensitive indicators of BCI, whether such injuries are significant in patients without clinical signs or symptoms remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the emergency clinician is to rapidly identify and initiate management for any surgically correctable lesion or life-threatening condition, and to identify those patients at risk for blunt cardiac injury (BCI) and initiate appropriate consultation and testing.",
"   </p>",
"   <p>",
"    The clinician should perform a standard bedside ultrasound examination (ie, Focused Assessment with Sonography for Trauma, or FAST). The FAST is an excellent screening test for clinically significant hemopericardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the FAST is nondiagnostic for hemopericardium, the clinician should obtain bedside echocardiography in any patient with blunt thoracic trauma and unexplained, persistent shock out of proportion to apparent injuries or despite aggressive resuscitation. A formal echocardiogram will better identify wall motion abnormalities and valvular disorders. Identified injuries are managed as described below. Clinicians must remember that hemorrhage remains the primary cause of traumatic shock, and consider other common noncardiac causes of shock (eg, tension pneumothorax). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An ECG and echocardiography should be obtained for patients with a history or clinical findings consistent with severe BCI. These may include signs of heart failure (eg, pulmonary edema, distended jugular veins) or abnormal heart sounds (eg, muffled sounds, holosystolic or diastolic murmur).",
"   </p>",
"   <p>",
"    A screening ECG is obtained in all blunt trauma patients with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain or tenderness",
"     </li>",
"     <li>",
"      History suggestive of heart disease (eg, accident preceded by syncope or shortness of breath)",
"     </li>",
"     <li>",
"      Active signs or symptoms consistent with heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with unexplained tachycardia that persists over several hours despite adequate fluid resuscitation and pain control, a new bundle branch block, or a significant arrhythmia are admitted for cardiac monitoring and likely echocardiography. In the rare case of the blunt thoracic trauma patient with evidence of myocardial infarction on ECG, serial biomarkers should be measured and immediate consultation with both cardiology and cardiac surgery obtained. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Electrocardiogram'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other patients without a history or clinical findings consistent with severe cardiac injury, but about whom concern persists, can be evaluated with repeat examinations, ECGs, and cardiac monitoring during a brief course of ED observation (four to six hours). A minimum of two ECGs, obtained toward the beginning and end of the observation period, should be performed.",
"   </p>",
"   <p>",
"    While controversy continues regarding the role of biomarkers, we do not routinely obtain a troponin in the stable patient with blunt chest trauma in the absence of significant ECG abnormalities, symptoms suggestive of ischemia, or age &lt;60 years. In the presence of such findings, it is reasonable to obtain a troponin at presentation and four to six hours thereafter. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiac biomarkers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient presentation and clinical findings determine management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5004323\">",
"    <span class=\"h2\">",
"     Myocardial or cardiac contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of a clear definition and accepted gold standard for testing makes the diagnosis of &ldquo;myocardial contusion&rdquo; or &ldquo;cardiac contusion&rdquo; difficult. Due to the ambiguity surrounding these traditional terms, we and many trauma researchers prefer to describe blunt cardiac injuries (BCIs) in terms of specific pathology (eg, septal rupture, myocardial infarction) or cardiac dysfunction (eg, diminished contractility in the absence of arrhythmia or hemorrhage) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/1,57-59\">",
"     1,57-59",
"    </a>",
"    ]. This approach avoids ambiguity and allows clinicians to manage patients based upon discrete problems identified through clinical evaluation and diagnostic testing. Such management is described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Valve, septum, or ventricular wall injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical or echocardiographic evidence of severe cardiac injury (eg, ruptured valve, septum, or ventricular wall; cardiac tamponade) require emergent surgical consultation.",
"   </p>",
"   <p>",
"    Induction agents with cardiodepressive effects and positive pressure ventilation following intubation may further compromise cardiac function in patients with these injuries. If possible (ie, patient is not in acute respiratory distress and is able to protect their airway), it may be helpful to delay intubation until the patient is in the operating room.",
"   </p>",
"   <p>",
"    If tamponade is suspected either clinically (eg, hypotension, distended jugular veins, muffled heart sounds) or identified by ultrasound, pericardiocentesis is performed. Tamponade that results from an atrial tear may be amenable to pericardiocentesis with periodic drainage using a pigtail catheter until definitive surgical repair can be performed.",
"   </p>",
"   <p>",
"    Among unstable patients who may not survive transfer to an operating room, emergency department (ED) thoracotomy, rather than pericardiocentesis, may be the best treatment for cardiac tamponade. Pericardiocentesis can be an effective temporizing measure, and may be attempted. Nevertheless, in the setting of blunt trauma, ED thoracotomy rarely results in successful resuscitation. ED thoracotomy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933905#H4933905\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Emergency department thoracotomy (EDT)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If cardiac injury is suspected in a hypotensive patient and rapid bedside ultrasound is unavailable to exclude tamponade or valvular injury, the cardiac surgery and cardiology services should be consulted immediately. Such patients should be admitted to a surgical service with cardiology consultation unless operative management is clearly unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of myocardial infarction (MI) in the setting of BCI is controversial due to the rarity of the disease and the frequent presence of multiple injuries. Catheterization with stenting may be the best approach, although some advocate bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/20,60,61\">",
"     20,60,61",
"    </a>",
"    ]. Thrombolytics are best avoided, unless both bypass surgery and angiography are unavailable. Although there are reports of successful treatment with thrombolytics, severe bleeding complications may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Management should be determined in consultation with cardiology. Cardiac surgery consultation is needed in the rare event that a coronary artery laceration or dissection is identified.",
"   </p>",
"   <p>",
"    For patients with features suggestive of BCI and in whom cardiac biomarkers are found to be elevated, cardiology consultation is obtained, and the patient is admitted for cardiac monitoring and further evaluation.",
"   </p>",
"   <p>",
"    A screening echocardiogram and cardiac biomarkers do NOT appear to add to the management of the hemodynamically stable patient without historical or clinical features suggestive of significant BCI, and we do not routinely obtain these tests [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnostic tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is warranted in patients with BCI for any clinical findings suggestive of hypotension or acute heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/40\">",
"     40",
"    </a>",
"    ]. Identified injuries are managed appropriately; patients without identifiable injury but with persistent dysfunction (eg, episodes of hypotension) are admitted for cardiac monitoring. Floor telemetry is appropriate for the patient with minor abnormalities, no significant concomitant injuries, and normal hemodynamics. All other patients should have a higher level of monitoring (eg, cardiac intensive care unit). Cardiology consultation is needed for any patient with hemodynamic instability in whom cardiac injury cannot be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have looked specifically at treatment of BCI-related arrhythmia, but most clinicians advocate management using standard ACLS protocols when necessary. In patients with a new arrhythmia (eg, high grade conduction blocks, new onset atrial fibrillation, supraventricular or ventricular tachycardia) following BCI, it is appropriate to perform a bedside echocardiogram to look for wall motion abnormalities or injuries that require emergent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Echocardiogram'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians should assume that hemorrhage is the cause of tachycardia in the trauma patient until proven otherwise. Once hemorrhage is ruled out, findings such as unexplained tachycardia that persists over several hours despite adequate fluid resuscitation and pain control, new bundle branch block, or arrhythmia raise concern for BCI. Patients with such findings are admitted for cardiac monitoring and likely echocardiography.",
"   </p>",
"   <p>",
"    Cardiology consultation is needed for any patient with a new arrhythmia (including persistent tachycardia), signs of heart failure, or hemodynamic instability likely due to cardiac dysfunction.",
"   </p>",
"   <p>",
"    Floor telemetry is appropriate for the patient with minor abnormalities (eg, intermittent premature ventricular or atrial contractions), no significant concomitant injuries, and normal hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/40,64,65\">",
"     40,64,65",
"    </a>",
"    ]. All other patients should have a higher level of monitoring. Established criteria for monitoring do not exist, but 24 to 48 hours of monitoring is reasonable for minor abnormalities. Rarely do abnormalities first present after 24 hours. If arrhythmias persist during monitoring, cardiology consultation should be obtained. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3406822\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10863031\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of blunt cardiac injury (BCI) in children are uncommon and thus it is difficult to know the precise incidence or to determine if these injuries occur by different mechanisms than in adults. Motor vehicle collisions (MVC) are routinely cited as the most common cause of BCI in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/7,66-68\">",
"     7,66-68",
"    </a>",
"    ]. As the majority of children are now restrained by seatbelts or car seats and sit in the back seats of cars, MVC may now account for fewer cases of BCI in children.",
"   </p>",
"   <p>",
"    BCI occurs in less than 5 percent of children with blunt thoracic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66,69,70\">",
"     66,69,70",
"    </a>",
"    ]. Myocardial contusions account for as much as 95 percent of these injuries; ventricular septal defects and papillary muscle rupture are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"     66",
"    </a>",
"    ]. According to a retrospective review, the thoracic and nonthoracic injuries most often associated with BCI in children include pulmonary contusion, rib or clavicle fractures, brain injury, and abdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10862825\">",
"    <span class=\"h2\">",
"     Presentation, diagnosis, and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to determine if children are more susceptible to blunt cardiac injury (BCI) than adults. However, the chest wall of a child is more compliant than the adult, and therefore during blunt thoracic trauma more kinetic energy can be transmitted to a child&rsquo;s intrathoracic structures without causing bony injury. Thus, BCI in children may go undiagnosed because external examination findings do not reflect the strength of the forces involved. Most BCIs in such cases are cardiac contusions that resolve on their own without any sequela, while most patients with a clinically significant BCI have some abnormal finding on chest examination, chest x-ray, or ECG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\", section on 'Anatomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Commotio cordis is a type of BCI that occurs with greater frequency in child athletes, most often as the result of a projectile (eg, baseball, hockey puck) striking the chest during a sensitive time during the cardiac cycle. Commotio cordis often results in ventricular fibrillation and sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"     \"Commotio cordis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike adults, children with BCI often have few presenting signs or symptoms so diagnosis may be more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/41,71\">",
"     41,71",
"    </a>",
"    ]. The presence of any of the following features in the setting of blunt trauma raises the possibility of clinically significant BCI:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ecchymosis, abrasions, or deformity of the chest wall",
"     </li>",
"     <li>",
"      Focal tenderness over superior ribs, sternum, or scapula",
"     </li>",
"     <li>",
"      Muffled heart tones or a new murmur",
"     </li>",
"     <li>",
"      Abnormal upper or lower extremity pulses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, according to a retrospective review, BCI in children is often associated with pulmonary contusion and rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"     66",
"    </a>",
"    ]. Signs of heart failure or hypotension in the setting of blunt thoracic trauma may be caused by BCI, but these findings are absent in many children and hypotension is far more likely to be due to hemorrhage. In the same retrospective series cited above, less than 25 percent of children with BCI had an abnormal cardiac examination. Of those with isolated BCI, 26 percent were hypotensive in the emergency department and less than 9 percent had signs of heart failure.",
"   </p>",
"   <p>",
"    The diagnostic approach to BCI in children is similar to adults (see",
"    <a class=\"local\" href=\"#H2505321\">",
"     'Evaluation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a bedside ultrasound (FAST examination) early in the assessment of any child with blunt thoracic trauma who is hemodynamically unstable. Ultrasound is ideal for identifying hemopericardium. If no hemopericardium is present but there is persistent concern for cardiogenic shock, a formal transthoracic echocardiogram looking for wall motion or",
"      <span class=\"nowrap\">",
"       valvular/septal",
"      </span>",
"      abnormalities should be obtained. In younger children, a transthoracic echocardiogram is generally preferred because it is less invasive, less difficult to perform, and usually provides sufficient information. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H24#H24\">",
"       \"Trauma management: Approach to the unstable child\", section on 'FAST (Focused Assessment with Sonography for Trauma)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtain a plain chest x-ray for any child with significant chest trauma. In cases of BCI, the x-ray may demonstrate cardiomegaly or reveal noncardiac injuries (eg, rib fractures).",
"     </li>",
"     <li>",
"      Obtain an electrocardiogram (ECG) in any child with chest pain, tenderness, chest wall ecchymosis, abnormal heart sounds, or abnormal upper or lower extremity pulses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When clinical and ECG findings suggest that BCI, rather than hemorrhage, may account for a child&rsquo;s hemodynamic instability, emergent transthoracic echocardiography should also be performed. Hemodynamically stable children with a normal sinus rhythm are unlikely to develop an arrhythmia or cardiac insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with adults, the appropriate use of cardiac troponin in the evaluation of children with possible BCI remains unclear. BCI is unlikely in an asymptomatic child with a cardiac troponin less than 1.05",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    at presentation and again within the first six hours of admission (it should be noted that baseline and threshold values for troponin vary by institution and assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/52,72\">",
"     52,72",
"    </a>",
"    ]. In addition, the clinical significance of an elevated troponin is questionable in a hemodynamically stable child with no examination findings suggestive of BCI and a normal ECG and chest x-ray. Therefore, we do not recommend obtaining a troponin in an asymptomatic child.",
"   </p>",
"   <p>",
"    Conversely, any child with an abnormal ECG and elevated troponin following blunt thoracic trauma warrants evaluation with transthoracic echocardiography and admission or close observation, including cardiac monitoring, for at least 24 hours. Troponin may be used as an adjunct in patients who are either clinically symptomatic (eg, arrhythmia, hypotension) or who have abnormal findings on chest x-ray or ECG.",
"   </p>",
"   <p>",
"    The general management and disposition of children with blunt thoracic trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .) In general, any child who has sustained significant blunt chest trauma and manifests any of the findings listed below suggestive of BCI should be admitted for observation, even in the absence of intrathoracic or intraabdominal injuries detected on imaging studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Abnormal ECG findings, including persistent sinus tachycardia",
"     </li>",
"     <li>",
"      Elevated cardiac troponin in association with concerning symptoms, signs, or abnormalities on ECG or cardiac monitoring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive management of BCI in children depends upon the specific injury sustained. Cardiac sequelae (such as mitral or tricuspid insufficiency or ventricular septal defect) may develop as the result of BCI. Consequently, all children with confirmed or suspected BCI should have a follow-up evaluation by a cardiologist with pediatric expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10862675\">",
"    <span class=\"h1\">",
"     PITFALLS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attributing shock in a trauma patient to cardiac injury rather than hemorrhage.",
"     </li>",
"     <li>",
"      Assuming that blunt cardiac injury with hemodynamic abnormalities is due to contused myocardium alone and not obtaining an echocardiogram to look for more severe injury (eg, valvular or septal rupture, pericardial tamponade).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome for patients with BCI correlates with the clinical findings at presentation. Factors associated with increased mortality include a high trauma severity score (eg, Injury Severity Score or Organ Injury Scale), a shorter time to diagnosis (implying more significant clinical findings), cardiac tamponade or rupture, absence of vital signs on admission, and coexistent injury to the aorta, liver, spleen, or kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/73\">",
"     73",
"    </a>",
"    ]. When the diagnosis is made due to an abnormal ECG or cardiac biomarker alone, outcome is favorable, with no long term sequelae in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27385/abstract/55,74,75\">",
"     55,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blunt cardiac injury is a poorly characterized disease with varied presentations and no clear diagnostic criteria. Injuries may include rupture of the ventricular or atrial wall, septum, or a valve; cardiac dysfunction; arrhythmia; or, rarely, myocardial infarction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology, definitions, and scoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Types of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard ACLS protocols are used to manage severe arrhythmia; immediate surgical consultation is required for severe injury, such as a valve tear, or septal or ventricular wall rupture. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Arrhythmia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Valve, septum, or ventricular wall injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography and cardiology consultation are necessary for any patient with blunt thoracic trauma and a complex arrhythmia, cardiac dysfunction, diastolic murmur (not known to be old), or signs of heart failure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening with serial electrocardiograms (ECGs), cardiac monitoring, and observation for four to six hours is sufficient in the hemodynamically stable patient for whom there is concern about BCI. We do not routinely obtain cardiac biomarkers in the stable patient with blunt chest trauma in the absence of ECG abnormalities or symptoms suggestive of ischemia, or unless the patient is 60 years or older. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiac biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest wall of a child is more compliant than the adult and therefore during blunt thoracic trauma more kinetic energy can be transmitted to a child&rsquo;s intrathoracic structures without bony injury. Thus, BCI can be difficult to diagnose in children because external signs of injury may be minimal or absent. When present, such external signs, focal tenderness over the upper thorax, or abnormal findings on the cardiac or pulse examinations raise the possibility of BCI. (See",
"      <a class=\"local\" href=\"#H3406822\">",
"       'Pediatric considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3205352\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/1\">",
"      Mattox KL, Flint LM, Carrico CJ, et al. Blunt cardiac injury. J Trauma 1992; 33:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/2\">",
"      Elie MC. Blunt cardiac injury. Mt Sinai J Med 2006; 73:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/3\">",
"      Martin M, Mullenix P, Rhee P, et al. Troponin increases in the critically injured patient: mechanical trauma or physiologic stress? J Trauma 2005; 59:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/4\">",
"      Fitzgerald M, Spencer J, Johnson F, et al. Definitive management of acute cardiac tamponade secondary to blunt trauma. Emerg Med Australas 2005; 17:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/5\">",
"      T&uuml;rk EE, Tsokos M. Blunt cardiac trauma caused by fatal falls from height: an autopsy-based assessment of the injury pattern. J Trauma 2004; 57:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/6\">",
"      Moore EE, Malangoni MA, Cogbill TH, et al. Organ injury scaling. IV: Thoracic vascular, lung, cardiac, and diaphragm. J Trauma 1994; 36:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/7\">",
"      Fulda G, Brathwaite CE, Rodriguez A, et al. Blunt traumatic rupture of the heart and pericardium: a ten-year experience (1979-1989). J Trauma 1991; 31:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/8\">",
"      Schultz JM, Trunkey DD. Blunt cardiac injury. Crit Care Clin 2004; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/9\">",
"      PARMLEY LF, MANION WC, MATTINGLY TW. Nonpenetrating traumatic injury of the heart. Circulation 1958; 18:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/10\">",
"      Mandavia DP, Hoffner RJ, Mahaney K, Henderson SO. Bedside echocardiography by emergency physicians. Ann Emerg Med 2001; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/11\">",
"      Leavitt BJ, Meyer JA, Morton JR, et al. Survival following nonpenetrating traumatic rupture of cardiac chambers. Ann Thorac Surg 1987; 44:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/12\">",
"      Namai A, Sakurai M, Fujiwara H. Five cases of blunt traumatic cardiac rupture: success and failure in surgical management. Gen Thorac Cardiovasc Surg 2007; 55:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/13\">",
"      De Maria E, Gaddi O, Navazio A, et al. Right atrial free wall rupture after blunt chest trauma. J Cardiovasc Med (Hagerstown) 2007; 8:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/14\">",
"      Cordovil A, Fischer CH, Rodrigues AC, et al. Papillary muscle rupture after blunt chest trauma. J Am Soc Echocardiogr 2006; 19:469.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/15\">",
"      Pasquier M, Sierro C, Yersin B, et al. Traumatic mitral valve injury after blunt chest trauma: a case report and review of the literature. J Trauma 2010; 68:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/16\">",
"      Wilke A, Kruse T, Hesse H, et al. Papillary muscle injury after blunt chest trauma. J Trauma 1997; 43:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/17\">",
"      Schwaitzberg SD, Khalil KG. Isolated traumatic aortic valvular insufficiency with rapid pulmonary deterioration. Report of two cases. Arch Surg 1985; 120:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/18\">",
"      Ismailov RM, Weiss HB, Ness RB, et al. Blunt cardiac injury associated with cardiac valve insufficiency: trauma links to chronic disease? Injury 2005; 36:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/19\">",
"      Bruschi G, Agati S, Iorio F, Vitali E. Papillary muscle rupture and pericardial injuries after blunt chest trauma. Eur J Cardiothorac Surg 2001; 20:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/20\">",
"      Foussas SG, Athanasopoulos GD, Cokkinos DV. Myocardial infarction caused by blunt chest injury: possible mechanisms involved--case reports. Angiology 1989; 40:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/21\">",
"      Lee DW, Garnic JD, Barlow GC. Acute anterior wall myocardial infarction secondary to blunt chest trauma--a case report. Angiology 1990; 41:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/22\">",
"      Jensen S, Kristensen IB, Kristensen BO. Lethal myocardial infarction subsequent to compression of the left anterior descending coronary artery induced by traumatic hematoma. Int J Legal Med 1992; 105:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/23\">",
"      Fu M, Wu CJ, Hsieh MJ. Coronary dissection and myocardial infarction following blunt chest trauma. J Formos Med Assoc 1999; 98:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/24\">",
"      Banzo I, Montero A, Uriarte I, et al. Coronary artery occlusion and myocardial infarction: a seldom encountered complication of blunt chest trauma. Clin Nucl Med 1999; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/25\">",
"      Yoon SJ, Kwon HM, Kim DS, et al. Acute myocardial infarction caused by coronary artery dissection following blunt chest trauma. Yonsei Med J 2003; 44:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/26\">",
"      Plautz CU, Perron AD, Brady WJ. Electrocardiographic ST-segment elevation in the trauma patient: acute myocardial infarction vs myocardial contusion. Am J Emerg Med 2005; 23:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/27\">",
"      Ismailov RM, Ness RB, Weiss HB, et al. Trauma associated with acute myocardial infarction in a multi-state hospitalized population. Int J Cardiol 2005; 105:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/28\">",
"      Patel R, Samaha FF. Right coronary artery occlusion caused by blunt trauma. J Invasive Cardiol 2000; 12:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/29\">",
"      Liedtke AJ, Allen RP, Nellis SH. Effects of blunt cardiac trauma on coronary vasomotion, perfusion, myocardial mechanics, and metabolism. J Trauma 1980; 20:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/30\">",
"      Liu B, Wang Z, Yang Z, et al. Experimental studies on the hemodynamic changes after thoracic impact injury. J Trauma 1996; 40:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/31\">",
"      Babu GG, Wood A, O'Callaghan P, et al. The complete array of electrocardiogram abnormalities secondary to myocardial contusion in a single case. Europace 2009; 11:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/32\">",
"      Cotter G, Moshkovitz Y, Barash P, et al. Ventricular fibrillation in the patient with blunt trauma: not always exsanguination. J Trauma 1996; 41:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/33\">",
"      Godbe D, Waxman K, Wang FW, et al. Diagnosis of myocardial contusion. Quantitative analysis of single photon emission computed tomographic scans. Arch Surg 1992; 127:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/34\">",
"      Helling TS, Duke P, Beggs CW, Crouse LJ. A prospective evaluation of 68 patients suffering blunt chest trauma for evidence of cardiac injury. J Trauma 1989; 29:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/35\">",
"      Bodin L, Rouby JJ, Viars P. Myocardial contusion in patients with blunt chest trauma as evaluated by thallium 201 myocardial scintigraphy. Chest 1988; 94:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/36\">",
"      Roy-Shapira A, Levi I, Khoda J. Sternal fractures: a red flag or a red herring? J Trauma 1994; 37:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/37\">",
"      Hills MW, Delprado AM, Deane SA. Sternal fractures: associated injuries and management. J Trauma 1993; 35:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/38\">",
"      Rashid MA, Ortenwall P, Wikstr&ouml;m T. Cardiovascular injuries associated with sternal fractures. Eur J Surg 2001; 167:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/39\">",
"      Juan CW, Wu FF, Lee TC, et al. Traumatic cardiac injury following sternal fracture: a case report and literature review. Kaohsiung J Med Sci 2002; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/40\">",
"      Clancy K, Velopulos C, Bilaniuk JW, et al. Screening for blunt cardiac injury: an Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg 2012; 73:S301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/41\">",
"      Milligan J, Potts JE, Human DG, Sanatani S. The protean manifestations of blunt cardiac trauma in children. Pediatr Emerg Care 2005; 21:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/42\">",
"      Sybrandy KC, Cramer MJ, Burgersdijk C. Diagnosing cardiac contusion: old wisdom and new insights. Heart 2003; 89:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/43\">",
"      Ismailov RM, Ness RB, Redmond CK, et al. Trauma associated with cardiac dysrhythmias: results from a large matched case-control study. J Trauma 2007; 62:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/44\">",
"      Hossack KF, Moreno CA, Vanway CW, Burdick DC. Frequency of cardiac contusion in nonpenetrating chest injury. Am J Cardiol 1988; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/45\">",
"      Nagy KK, Krosner SM, Roberts RR, et al. Determining which patients require evaluation for blunt cardiac injury following blunt chest trauma. World J Surg 2001; 25:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/46\">",
"      Karalis DG, Victor MF, Davis GA, et al. The role of echocardiography in blunt chest trauma: a transthoracic and transesophageal echocardiographic study. J Trauma 1994; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/47\">",
"      van Wijngaarden MH, Karmy-Jones R, Talwar MK, Simonetti V. Blunt cardiac injury: a 10 year institutional review. Injury 1997; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/48\">",
"      Labovitz AJ, Noble VE, Bierig M, et al. Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr 2010; 23:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/49\">",
"      Chirillo F, Totis O, Cavarzerani A, et al. Usefulness of transthoracic and transoesophageal echocardiography in recognition and management of cardiovascular injuries after blunt chest trauma. Heart 1996; 75:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/50\">",
"      Collins JN, Cole FJ, Weireter LJ, et al. The usefulness of serum troponin levels in evaluating cardiac injury. Am Surg 2001; 67:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/51\">",
"      Jackson L, Stewart A. Best evidence topic report. Use of troponin for the diagnosis of myocardial contusion after blunt chest trauma. Emerg Med J 2005; 22:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/52\">",
"      Rajan GP, Zellweger R. Cardiac troponin I as a predictor of arrhythmia and ventricular dysfunction in trauma patients with myocardial contusion. J Trauma 2004; 57:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/53\">",
"      Salim A, Velmahos GC, Jindal A, et al. Clinically significant blunt cardiac trauma: role of serum troponin levels combined with electrocardiographic findings. J Trauma 2001; 50:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/54\">",
"      Biffl WL, Moore FA, Moore EE, et al. Cardiac enzymes are irrelevant in the patient with suspected myocardial contusion. Am J Surg 1994; 168:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/55\">",
"      Bertinchant JP, Polge A, Mohty D, et al. Evaluation of incidence, clinical significance, and prognostic value of circulating cardiac troponin I and T elevation in hemodynamically stable patients with suspected myocardial contusion after blunt chest trauma. J Trauma 2000; 48:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/56\">",
"      Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of clinically significant blunt cardiac injury. J Trauma 2003; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     Pasquale MD, Nagy K, Clarke J. Practice Management Guidelines for Screening of Blunt Cardiac Injury. Eastern Association for the Surgery of Trauma. 1998.",
"    </li>",
"    <li>",
"     Asensio JA, Garcia-Nunez LM, Petrone P. Trauma to the Heart. In: Trauma, 6th, Feliciano DV, Mattox KL, Moore EE.  (Eds), McGraw Hill, New York 2008.",
"    </li>",
"    <li>",
"     Conn A. Chest Trauma. In: Trauma: A Comprehensive Emergency Medicine Approach, Legome E, Shockley LW.  (Eds), Cambridge University Press, Cambridge 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/60\">",
"      Dahle TG, Berger A, Tuna N, Das G. Coronary artery stenting for acute myocardial infarction secondary to mild, blunt chest trauma in a soccer player. J Invasive Cardiol 2005; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/61\">",
"      Thorban S, Ungeheuer A, Blasini R, Siewert JR. Emergent interventional transcatheter revascularization in acute right coronary artery dissection after blunt chest trauma. J Trauma 1997; 43:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/62\">",
"      Calvo Orbe L, Garcia Gallego F, Sobrino N, et al. Acute myocardial infarction after blunt chest trauma in young people: need for prompt intervention. Cathet Cardiovasc Diagn 1991; 24:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/63\">",
"      Ledley GS, Yazdanfar S, Friedman O, Kotler MN. Acute thrombotic coronary occlusion secondary to chest trauma treated with intracoronary thrombolysis. Am Heart J 1992; 123:518.",
"     </a>",
"    </li>",
"    <li>",
"     Conn A. Chest trauma. In: Trauma: A Comprehensive Emergency Medicine Approach, 1st, Legome E, Shockley LW.  (Eds), Cambridge University Press, New York 2011. p.190.",
"    </li>",
"    <li>",
"     Asensio JA, Garcia-Nunez LM, Patrizio P. Trauma to the heart. In: Trauma, 6th, Feliciano D, Mattox K, Moore E.  (Eds), McGraw Hill Medical, New York 2008. p.569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/66\">",
"      Dowd MD, Krug S. Pediatric blunt cardiac injury: epidemiology, clinical features, and diagnosis. Pediatric Emergency Medicine Collaborative Research Committee: Working Group on Blunt Cardiac Injury. J Trauma 1996; 40:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/67\">",
"      Scorpio RJ, Wesson DE, Smith CR, et al. Blunt cardiac injuries in children: a postmortem study. J Trauma 1996; 41:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/68\">",
"      Bromberg BI, Mazziotti MV, Canter CE, et al. Recognition and management of nonpenetrating cardiac trauma in children. J Pediatr 1996; 128:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/69\">",
"      Cooper A, Barlow B, DiScala C, String D. Mortality and truncal injury: the pediatric perspective. J Pediatr Surg 1994; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/70\">",
"      Tiao GM, Griffith PM, Szmuszkovicz JR, Mahour GH. Cardiac and great vessel injuries in children after blunt trauma: an institutional review. J Pediatr Surg 2000; 35:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/71\">",
"      Sartorelli KH, Vane DW. The diagnosis and management of children with blunt injury of the chest. Semin Pediatr Surg 2004; 13:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/72\">",
"      Hirsch R, Landt Y, Porter S, et al. Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury. J Pediatr 1997; 130:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/73\">",
"      Lancey RA, Monahan TS. Correlation of clinical characteristics and outcomes with injury scoring in blunt cardiac trauma. J Trauma 2003; 54:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/74\">",
"      Lindstaedt M, Germing A, Lawo T, et al. Acute and long-term clinical significance of myocardial contusion following blunt thoracic trauma: results of a prospective study. J Trauma 2002; 52:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27385/abstract/75\">",
"      Sturaitis M, McCallum D, Sutherland G, et al. Lack of significant long-term sequelae following traumatic myocardial contusion. Arch Intern Med 1986; 146:1765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 359 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27385=[""].join("\n");
var outline_f26_47_27385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY, DEFINITIONS, AND SCORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY AND MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREHOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Types of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2505321\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2505328\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cardiac biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5004323\">",
"      Myocardial or cardiac contusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Valve, septum, or ventricular wall injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3406822\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10863031\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10862825\">",
"      Presentation, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10862675\">",
"      PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3205352\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/21/26972\" title=\"table 1\">",
"      Cardiac injury scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=related_link\">",
"      Emergency ultrasound in adults with abdominal and thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_47_27386="Major side effects of systemic glucocorticoids";
var content_f26_47_27386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of systemic glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Kenneth G Saag, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Eric L Matteson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/47/27386/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/47/27386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders, and the toxicity of glucocorticoids is one of the commonest causes of iatrogenic illness associated with chronic inflammatory disease. Recognition of these toxicities, many of which are similar to the findings in spontaneous (endogenous) Cushing&rsquo;s syndrome, is of value in their prevention and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous toxicities, or adverse effects (AEs), have been attributed to glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef65998 \" href=\"UTD.htm?15/62/16365\">",
"     table 1",
"    </a>",
"    ). However, the attribution of causality to the glucocorticoids alone cannot always be clearly established. Other factors that may contribute to such AEs include the nature and severity of the underlying disease being treated and the other medications being administered concurrently. Estimates of the frequency and severity of AEs, as well as the respective dose and duration of therapy that may result in such AEs, are also limited by the modest number of prospective trials that address this question. The benefits of these medications in critical illness and the morbidity of some of the AEs make such prospective data acquisition in randomized trials of sufficient duration unlikely.",
"   </p>",
"   <p>",
"    The AEs seen specifically with systemic (oral and parenteral) glucocorticoid therapy will be reviewed here. The AEs resulting from the use of inhaled, topical, and intraarticular glucocorticoids; glucocorticoid withdrawal; and the clinical manifestations of endogenous glucocorticoid excess are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link\">",
"     \"Joint aspiration or injection in adults: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24131064\">",
"    <span class=\"h1\">",
"     MECHANISM OF ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects (AEs) of glucocorticoids are more common in patients receiving these drugs in high doses or over a long period of time. Glucocorticoids used in chronic disease (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) do not have significant mineralocorticoid, androgenic, or estrogenic activity; thus, their major AEs result from inhibition of hypothalamic-pituitary-adrenal function and the development of iatrogenic Cushing&rsquo;s syndrome. The relative frequency of features of endogenous Cushing&rsquo;s syndrome and the iatrogenic syndrome vary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'Complications of chronic use'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of glucocorticoids are mediated by cytosolic glucocorticoid receptors and result from both genomic and nongenomic mechanisms that also have a role in the therapeutic effects of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The adverse effects appear to result largely from transactivation that leads to increased expression of regulatory and antiinflammatory proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/2\">",
"     2",
"    </a>",
"    ]; by contrast, many of the clinically desirable effects appear to result primarily from transrepression, which results in the decreased production of proinflammatory proteins. Nongenomic effects of glucocorticoids include rapid, nonspecific interactions of glucocorticoids with cellular membranes, nongenomic effects medicated by cytosolic glucocorticoid receptors, and specific interactions with membrane-bound glucocorticoid receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid toxicity is generally related to both the average dose and cumulative duration of use, although, for most toxicities, a &ldquo;threshold&rdquo; dose or duration has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"     4",
"    </a>",
"    ]. Controversy exists over the relative safety of &ldquo;low-dose&rdquo; glucocorticoid use (less than or equal to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent) in chronic conditions such as rheumatoid arthritis (RA). Several large retrospective reviews have shown that long-term glucocorticoid use, even in low doses, is a significant independent predictor of numerous serious AEs and that risk is both dose and time dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other analyses note a paucity of evidence documenting toxicity from the use of very low doses of glucocorticoids (eg, prednisone &lt;5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    such as those sometimes used for the treatment of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"     4",
"    </a>",
"    ]. The following studies illustrate the range of observations regarding the influence of dose and duration of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of patients with RA found that the average daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose was the strongest predictor of a serious AE potentially attributable to glucocorticoid therapy (odds ratio = 4.5 for 5 to 10 mg, and 32.3 for 10 to 15 mg) (",
"      <a class=\"graphic graphic_figure graphicRef53432 \" href=\"UTD.htm?19/45/20190\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/5\">",
"       5",
"      </a>",
"      ]. This glucocorticoid-AE association persisted after statistical adjustment for significant disease severity factors, such as the presence of rheumatoid nodules and bony erosions. However, glucocorticoid use in RA is associated with disease severity and degree of disability, which makes the results of observational uncontrolled studies more difficult to interpret with a high level of confidence [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of the published literature and of the adverse event (AE) data from four randomized trials of low dose glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      involving 568 patients with RA found a paucity of high quality evidence regarding the degree of risk from low-dose glucocorticoids and only small numbers of AEs associated with glucocorticoid use in the randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"       4",
"      </a>",
"      ]. However, the prospective trials were not primarily designed to detect adverse effects, and patients were followed for only two years. The following observations were made in the analysis of these four randomized trials:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One study showed increased hyperglycemia associated with use of low-dose glucocorticoids, but no cases of new onset diabetes were reported.",
"     </li>",
"     <li>",
"      Low-dose glucocorticoid use was associated with an increase in body weight of 4 to 8 percent over two years, which reached significance compared with placebo in two of the four trials.",
"     </li>",
"     <li>",
"      In the two studies involving a total of 273 patients in which ophthalmologic examinations were performed, there were 4 patients on low-dose glucocorticoids reported with glaucoma, but there were no cases among in the controls. The incidence of cataracts was not increased.",
"     </li>",
"     <li>",
"      Low-dose glucocorticoid therapy, when compared with placebo, was not associated during the trials with an increased loss of bone mineral density, any reports of avascular necrosis, myopathy, decreased libido, excess cardiovascular events or heart disease, increased blood pressure, serious cutaneous adverse effects, upper GI ulcers or bleeding, pancreatitis, increased risk of infection, psychosis, or mood disturbance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a mail survey of 6517 patients receiving glucocorticoid treatment (mean dose &plusmn; standard deviation [SD] of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent of 16 &plusmn; 14",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for various conditions for at least 60 days, over 90 percent of patients reported at least one of eight AEs commonly associated with glucocorticoid use [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/8\">",
"       8",
"      </a>",
"      ]. At least one AE rated as very bothersome was reported by 55 percent of patients. Weight gain was the most common AE reported (70 percent). Skin bruising or thinning and sleep disturbance were also common. Cataracts occurred in 15 percent, and fractures occurred in 12 percent.",
"      <br/>",
"      <br/>",
"      There was a strong association with cumulative glucocorticoid dose of all eight AEs that were assessed. In patients receiving low doses (prednisone &le;7.5",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      increasing duration of use (greater than 90 days) was associated with acne, skin bruising, weight gain, and cataracts. Increases in the daily dose within the low-dose range (0 to 7.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      were more strongly associated with fractures and sleep disturbance than was increased duration of use. The degree of bias introduced by a low response rate (of 38 percent) is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TOXICITY OF SYSTEMIC GLUCOCORTICOIDS BY ORGAN SYSTEM OR SYMPTOM COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have adverse effects (AE) on many organ systems (",
"    <a class=\"graphic graphic_table graphicRef65998 \" href=\"UTD.htm?15/62/16365\">",
"     table 1",
"    </a>",
"    ). AEs range from those that are not necessarily serious but are displeasing to patients (eg, Cushingoid appearance) to those that are life-threatening (eg, serious infections). Unfortunately, some AEs, such as accelerated reductions in bone mineral density or early cataracts, may be largely asymptomatic until later manifestations develop that require medical attention (eg, acute vertebral collapse, cataract requiring surgical extraction). Estimates of the frequency of particular adverse effects vary between studies and depend in part on the specific condition being treated and on the glucocorticoid treatment regimen being used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/9\">",
"     9",
"    </a>",
"    ]. With the exception of cataracts, a potential acceleration in atherosclerotic vascular disease, and, to a lesser degree, bone effects (osteoporosis and osteonecrosis), all glucocorticoid toxicity is at least partially reversible over time with glucocorticoid discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Skin and soft tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the most common toxicities attributable to glucocorticoids are skin thinning and purpura. Skin changes were seen in 46 percent of patients treated for three months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at doses greater than 20 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/10\">",
"     10",
"    </a>",
"    ]. Glucocorticoid-associated purpura often affects the sun exposed areas of the dorsum of the hand and forearm and is not accompanied by palpable swelling. Data from a large arthritis cohort suggest that 32 cases of purpura develop for every 1000 patient-years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the patient with macular skin lesions\", section on 'Solar purpura (senile purpura)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-melanoma skin cancers (squamous cell and basal cell types) may be more frequent in patients who use oral glucocorticoids. The risk of squamous and basal cell skin cancer was increased in oral glucocorticoid users compared with age and sex matched case controls without skin cancer in one study (odds ratios 2.31 and 1.49, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/12\">",
"     12",
"    </a>",
"    ]; a similar increased risk was noted in another retrospective study population with observed to expected incidence rates (standardized incidence ratio or SIR) of 2.45 and 1.52, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/13\">",
"     13",
"    </a>",
"    ]. Other dermatologic AEs include &ldquo;steroid acne,&rdquo; alopecia, hypertrichosis, and striae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cushingoid appearance and weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of Cushingoid features (redistribution of body fat with truncal obesity, buffalo hump, and moon face) and weight gain are quite troubling to patients; the risk of these complications is both dose and duration dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 799 patients with rheumatoid arthritis, adverse effects in patients treated with glucocorticoids for at least six months were compared with those in patients who had not received glucocorticoids for at least 12 months at the time of evaluation; weight gain was more frequent in patients treated with at least 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent, compared with those who had not received any for at least 12 months (22.4 versus 9.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/14\">",
"       14",
"      </a>",
"      ]. However, there was a threshold effect, such that the rate of weight gain was not increased in those who took less than 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (8.7 percent) or further increased at doses greater than 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (21.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cushingoid features showed a linear increase in frequency with dose rather than a threshold effect. Only 2.7 percent of patients who had not received glucocorticoids in the prior 12 months exhibited such changes, compared with 4.3, 15.8, and 24.6 percent of patients who had received &lt;5, 5 to 7.5, and &gt;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of prednisone or equivalent, respectively.",
"     </li>",
"     <li>",
"      In a survey of 2167 long-term users of glucocorticoids (mean",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent dose &plusmn; SD of 16 &plusmn; 14",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for &ge;60 days), weight gain was the most common self-reported adverse event (70 percent of patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/8\">",
"       8",
"      </a>",
"      ]. In those on &le;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of prednisone or equivalent, increasing duration of use was significantly associated with weight gain.",
"     </li>",
"     <li>",
"      In an analysis of four prospective trials of glucocorticoids in rheumatoid arthritis, the use of 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent over two years was associated with an increase of mean body weight of 4 to 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Cushingoid appearance may occur within the first two months of therapy. Alternate day therapy, which causes less hypothalamic pituitary adrenal axis suppression, may result in a lower incidence of Cushingoid changes. However, the likelihood of developing such changes remains dose dependent in our experience, and alternate day therapy does not prevent their occurrence.",
"   </p>",
"   <p>",
"    Factors which may contribute to increased weight also include an increased appetite, a common side effect of glucocorticoid therapy, and an increase in food intake for symptomatic relief in patients with gastropathy or peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Progressive obesity'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Gastrointestinal tract'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of both cataracts and glaucoma is increased in patients on glucocorticoids and is dose-related [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients on prolonged moderate- to high-dose therapy should be examined periodically by an ophthalmologist to promote early detection of cataracts and glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cataracts commonly occur after prolonged glucocorticoid use. These cataracts share the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They occur in a posterior subcapsular location and can usually be distinguished from senile cataracts.",
"     </li>",
"     <li>",
"      They are often bilateral and develop slowly.",
"     </li>",
"     <li>",
"      Children are more susceptible than adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H9#H9\">",
"       \"Cataract in children\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be no minimal safe dose with respect to the risk of cataract formation, although risk is dose and time dependent and is more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses greater than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or with medications that have been administered for more than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In a study that evaluated 122 patients with RA taking a mean dose of prednisone of 8.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for an average of 6.9 years, 29 percent developed cataracts compared with 18 percent of matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/6\">",
"     6",
"    </a>",
"    ]. Another study of patients with rheumatoid arthritis receiving a mean dose of 6 mg of prednisone daily for a mean of 6 years also found cataracts more common in patients on glucocorticoids than in patients not using prednisone (15 versus 4.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids can also increase intraocular pressure, but these effects can usually be controlled with appropriate medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. This form of glaucoma occurs most commonly in patients who use glucocorticoid eye drops, although it has been observed in chronic and, to a lesser extent, acute systemic glucocorticoid use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of glaucoma or worsening intraocular pressure is greater in patients on glucocorticoids who are otherwise predisposed to this disorder or who have certain comorbidities, including those with a positive family history of glaucoma diabetes mellitus or high myopia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4,21\">",
"     4,21",
"    </a>",
"    ]. In patients with pre-existing open- or closed-angle glaucoma, the use of glucocorticoids will frequently aggravate the condition (46 to 92 and 65 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exophthalmos and swelling of the lids and ocular muscles are rare ophthalmologic complications of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rare adverse effect of systemic, local, or even topical use of glucocorticoids is central serous chorioretinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. This type of chorioretinopathy is associated with edema formation that can separate the retina from the choroid. Reduction of glucocorticoid dose is the most important element of treatment, if it can be done without causing a dangerous exacerbation of the disease that is being treated with the glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid use is associated with an increased risk of serious adverse cardiovascular events, particularly ischemic heart disease and heart failure, just as atherosclerosis is accelerated and cardiovascular risk is increased in patients with hypercortisolism due to Cushing's disease; this risk is dose dependent and may be low or absent in patients on low-dose glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/29\">",
"     29",
"    </a>",
"    ]. The relative risks of ischemic heart disease versus heart failure or stroke may differ depending upon the condition being treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic use of supraphysiologic doses of glucocorticoids has been associated with increased rates of myocardial infarction, stroke, heart failure, and all-cause mortality. The following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased cardiovascular disease was associated with glucocorticoid use at doses &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in a population-based study that compared 68,781 patients for whom glucocorticoids were prescribed with 82,202 nonusers; none of these patients had been hospitalized previously for cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/29\">",
"       29",
"      </a>",
"      ]. The rate of cardiovascular disease (a composite of myocardial infarction, angina, coronary revascularization, hospitalization for heart failure, transient ischemic attack or stroke), adjusted for other measured risk factors, was significantly higher in patients who were prescribed high doses of glucocorticoids (defined as &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of prednisone or its equivalent), compared with those who had not received glucocorticoids (absolute risk difference 59 events per 1000 patient-years, adjusted rate ratio 2.6). Such risk was not increased in patients receiving less than 7.5 mg prednisone daily.",
"      <br/>",
"      <br/>",
"      Risk of the composite end point was higher for patients who had continuing prescriptions than for those receiving intermittent glucocorticoid prescriptions and was higher for users of glucocorticoids during the six months prior to the event compared with use at an earlier time.",
"      <br/>",
"      <br/>",
"      The risks of heart failure, myocardial infarction, a combination of stroke and transient ischemic attacks (TIA), and all-cause mortality were each significantly higher for those prescribed high-dose glucocorticoids (rate ratios of 3.7, 3.3, 1.7, and 7.4, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/29\">",
"       29",
"      </a>",
"      ]. The risk of heart failure appeared to increase with higher daily glucocorticoid doses.",
"     </li>",
"     <li>",
"      Similar associations between glucocorticoid use and ischemic heart disease and heart failure were noted in another large retrospective case-control study [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/30\">",
"       30",
"      </a>",
"      ]. Current glucocorticoid use was associated with significantly increased risks of heart failure and ischemic heart disease (adjusted odds ratios 2.7 and 1.2, respectively) but not with stroke or TIA. The risk was greater at higher doses and with current, compared with past, use. The relation of current glucocorticoid use with heart failure was greatest for patients with chronic obstructive pulmonary disease (COPD) compared with patients with RA or with neither RA nor COPD. The risk of ischemic heart disease for current users was increased in both patients with RA and those with COPD, but not in patients with neither RA nor COPD",
"     </li>",
"     <li>",
"      Adverse cardiovascular outcomes, including myocardial infarction, heart failure, peripheral vascular disease, and cerebrovascular disease, were not significantly increased in patients treated with glucocorticoids for polymyalgia rheumatica and subsequently followed for a median of 7.6 years, compared with patients treated with nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/31\">",
"       31",
"      </a>",
"      ]. A trend for a protective effect of glucocorticoids was seen compared with NSAID treatment, particularly when the outcomes were taken together.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of iatrogenic Cushing syndrome may be a marker for patients at a higher risk of cardiovascular disease. A cohort of 547 patients diagnosed with Cushing syndrome associated with glucocorticoid use in a large general practice database had a significantly greater risk of a cardiovascular event compared with 3231 age- and sex-matched patients, who were receiving similar doses of glucocorticoids (initial median dose of 25 to 28 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , interquartile range of 5 to 45 mg, and median duration of 8.4 to 9.6 months, interquartile range of 2.5 to 25.5 months) but who did not have a diagnosis of Cushing syndrome, and compared with 3282 patients who did not receive glucocorticoids (incidence rates of risk per 100 person-years: 15.1, 95% CI 11.8-18.4, versus 6.4, 95% CI 5.5-7.3, versus 4.1, 95% CI 3.4-4.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/32\">",
"     32",
"    </a>",
"    ]. The increased risks compared with both sets of controls remained after adjustment for multiple potential confounding variables (adjusted hazard ratios of 2.74, 95% CI 2.06-3.62, and 4.16, 95% CI 2.98-5.82).",
"   </p>",
"   <p>",
"    An association of glucocorticoid use with risk of atrial fibrillation and flutter has been reported in two small observational studies and in a larger population-based, case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In the latter study, current glucocorticoid use was more common among 20,221 patients with atrial fibrillation or flutter than in 202,130 population controls (6.4 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/35\">",
"     35",
"    </a>",
"    ]. Currently using glucocorticoids was associated with a significant increased risk of atrial fibrillation or flutter, compared with never having used glucocorticoids (adjusted odds ratio, OR, 1.9). Risk was increased for new users and long-term users, but not for former users (OR 3.6, 1.7, and 1.0, respectively), and was unrelated to whether or not pulmonary or cardiovascular disease was present.",
"   </p>",
"   <p>",
"    Serious adverse cardiovascular toxicities, including sudden death, have been reported in occasional patients who have been given pulse infusions of glucocorticoids (eg, 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for multiple infusions) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/36\">",
"     36",
"    </a>",
"    ]. In many of these cases, however, it was difficult to determine whether this AE was more likely attributable to glucocorticoids or to the underlying disorder necessitating the therapy. Thus, cardiac monitoring is indicated in patients with significant cardiac disease who are treated with pulse glucocorticoid therapy, especially those on diuretics, the use of which may also be associated electrolyte disturbances such as hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of glucocorticoids on atherosclerotic vascular disease is thought to be mediated in part by elevated lipoprotein levels. However, the results of studies performed to analyze this issue have had mixed results, and beneficial effects of glucocorticoids on dyslipidemia have also been observed. In one report, moderate- to low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    tapered to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    over three months) had no significant adverse effect on lipoprotein levels if other risk factors were taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/37\">",
"     37",
"    </a>",
"    ]. Another observational study concluded that glucocorticoid use was associated with a more favorable lipid profile in older adults (&ge;60 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/38\">",
"     38",
"    </a>",
"    ]. Studies in patients with systemic lupus erythematosus (SLE) have indicated that the adverse effects of glucocorticoids on lipid profiles are dose dependent, occurring only at prednisone doses greater 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretation of these data is complicated by the difficulty of distinguishing effects due to disease activity, which itself may be associated with increased cardiovascular risk and lipid abnormalities, from effects directly related to the medications themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids may act by leading sequentially to peripheral insulin resistance, hyperinsulinemia, and increased hepatic VLDL synthesis. However, glucocorticoid-induced reduction in ACTH release also contributes to the lipid changes. In one report, for example, the administration of ACTH for three weeks to nine hyperlipidemic, glucocorticoid-treated patients (five of whom were transplant recipients) led to substantial reductions in total and LDL-cholesterol and triglycerides and to an increase in HDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/43\">",
"     43",
"    </a>",
"    ]. ACTH may act, in part, by up-regulating LDL receptor activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids independently increase the risk for a number of adverse gastrointestinal (GI) events, such as gastritis, ulcer formation, and GI bleeding. However, the risk of peptic ulcer disease due to glucocorticoids alone is low, rises significantly when they are used in combination with nonsteroidal antiinflammatory drugs (NSAIDs), and is also lower than the risk with NSAIDs alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated relative risks of glucocorticoids alone vary from 1.1 (not significant) to 1.5 (marginally significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the combination of glucocorticoids and NSAIDs results in a synergistic increase in the incidence of GI events as shown by the following findings from two meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid use is associated with a nearly twofold increased risk of a gastrointestinal AE among patients also taking NSAIDs when compared with those who use NSAIDs alone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of NSAIDs and glucocorticoids is associated with a fourfold increased risk of a gastrointestinal AE compared with nonuse of either drug [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether substitution of a selective COX-2 inhibitor for a nonselective NSAID would lower this risk is unclear.",
"   </p>",
"   <p>",
"    We suggest NOT using prophylaxis against gastrointestinal bleeding in patients taking glucocorticoids alone. By contrast, patients taking glucocorticoids in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAIDs may require prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a variety of other GI complications that can occur in glucocorticoid users, including visceral perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/47-49\">",
"     47-49",
"    </a>",
"    ] and hepatic steatosis (fatty liver) that can rarely lead to systemic fat embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids may mask the symptoms of serious gastrointestinal disease, an effect that may account, in part, for the increased risk of perforated sigmoid diverticular abscess associated with their use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22923416\">",
"    <span class=\"h3\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of glucocorticoids in causing acute pancreatitis is uncertain. While there is some evidence suggesting an etiologic role for glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], other studies, particularly in patients with systemic lupus erythematosus, have shown that the disease is causative, rather than the drugs, which may be beneficial therapeutically [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large population-based nested case control study analyzed 6161 cases of acute pancreatitis and 61,637 controls. It found an increased risk for acute pancreatitis among the current users of oral glucocorticoids compared with nonusers (OR 1.53, 95% CI 1.27-1.84), but whether the analysis was able to adequately control for all relevant confounders was not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/54\">",
"     54",
"    </a>",
"    ]. Risk was highest from 4 to 14 days after the drug was dispensed but was not elevated prior to that interval; risk gradually decreased after two weeks, returning to baseline within one to two months. Large prospective epidemiologic studies will be required to more clearly define the relationship of newly started glucocorticoid therapy with the onset of pancreatitis, particularly in the absence of data from randomized trials. The risk of pancreatitis in patients receiving long-term glucocorticoids also remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Kidney and systemic hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have a number of dose dependent effects on renal function and systemic hemodynamics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher dose glucocorticoids commonly promote fluid retention, a particular concern to patients with underlying heart or kidney disease. This is not a problem in normal subjects because of the phenomenon of mineralocorticoid escape which prevents progressive fluid overload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoid therapy can raise the blood pressure in both normotensive and hypertensive subjects. How this occurs is not well-understood [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Hypertension and cardiovascular risk'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Long-term use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in patients with RA may be associated with a higher risk of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. However, in patients receiving low doses of glucocorticoids (eg, 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of prednisone), significant hypertension may be better explained by age and initial blood pressure than by the glucocorticoids themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kaliuresis occurs early with glucocorticoid therapy. Rapid administration of high doses can result in the development of hypokalemia and metabolic alkalosis. However, clinically significant hypokalemia is uncommon with routine exogenous glucocorticoid use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genitourinary and reproductive system",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of glucocorticoids can cause menstrual irregularities in women and can lower fertility in both men and women. How this occurs is not well-understood, but inhibition of sex hormone production may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid use in pregnancy may increase the risk of cleft palate in offspring, but the absolute risk is likely low. There is no convincing evidence that glucocorticoids cause fetal adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more serious glucocorticoid-induced adverse effects is osteoporosis, which is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1676923\">",
"    <span class=\"h3\">",
"     Vertebral fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of vertebral fractures in glucocorticoid-treated patients with bone mineral density that is within the normal range suggests that mechanisms in addition to glucocorticoid-induced osteopenia and osteoporosis contribute to increased bone fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/64\">",
"     64",
"    </a>",
"    ]. Increased osteocyte and osteoblast death by apoptosis and inhibition of osteoblast generation may allow accumulation of microfractures and may increase the risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis (avascular or ischemic necrosis of bone) is a significant problem, particularly with high doses of glucocorticoids. Glucocorticoid-induced osteonecrosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H3#H3\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Growth in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth impairment is commonly seen in children receiving glucocorticoids. The effect is most pronounced with daily therapy, may be less with an alternate-day regimen, and can occur with inhaled glucocorticoids. In boys, the loss of height (mean 4 cm in one study) may be permanent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of short stature\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathy is an infrequent complication of glucocorticoid therapy. It typically presents as proximal motor weakness in both the upper and lower extremities. Glucocorticoid-induced myopathy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More acute and severe weakness noted in critically ill patients has been attributed at least in part to the use of glucocorticoids. Variously referred to as critical illness myopathy and acute quadriplegic myopathy, it has also been suspected to be due to an interaction between glucocorticoids and neuromuscular blocking agents. This is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuromuscular weakness related to critical illness\", section on 'Critical illness myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids induce a range of psychiatric and cognitive symptoms, which depend upon dose and duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/67\">",
"     67",
"    </a>",
"    ]. In most patients, these symptoms are mild and reversible, but emotional lability; hypomania; mania; depression; psychosis; delirium, confusion, or disorientation (which are more common in older patients); and cognitive changes including memory deficits may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Disturbances in sleep are reported, especially with split doses that may interfere with the normal pattern of diurnal cortisol production. Akathisia (motor restlessness) is a common glucocorticoid side effect. The risk of developing a given neuropsychiatric disorder following glucocorticoid therapy may be increased among patients with a past history of that condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/69\">",
"     69",
"    </a>",
"    ]. Older patients may be at higher risk for depression; mania; and delirium, confusion, or disorientation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/69\">",
"     69",
"    </a>",
"    ]. The following conditions and observations illustrate the range of reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mood disorders &mdash; Patients receiving glucocorticoids often experience an improved sense of well-being within several days of starting the medications, even prior to improvement in the status of the underlying disease; mild euphoria or anxiety may also be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/68,70,71\">",
"       68,70,71",
"      </a>",
"      ]. Hypomanic reactions and activated states are more common early in therapy than is depression, but the prevalence of depression is greater in patients on more longstanding therapy, even on low to moderate doses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/68,70,72\">",
"       68,70,72",
"      </a>",
"      ]. Patients with a family history of depression or alcoholism are at increased risk for affective diseases when given glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/73\">",
"       73",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      More severe psychiatric symptoms can occur quickly, within a few days, in patients receiving high doses of glucocorticoids. As an example, in one prospective but uncontrolled study of 50 patients receiving over 75 to 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent for greater than a week for various ophthalmologic indications, hypomanic symptoms were induced in about 30 percent, and depressive symptoms in about 10 percent, of patients by the end of one week [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/74\">",
"       74",
"      </a>",
"      ]. No patient became overtly psychotic, demented, or delirious.",
"     </li>",
"     <li>",
"      Psychosis &mdash; Psychosis can occur but does so almost exclusively at doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      above 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      given for a prolonged period [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/4,75,76\">",
"       4,75,76",
"      </a>",
"      ]. Approximately 10 percent of patients have persistent symptoms that may require treatment despite reduction of glucocorticoid dose [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/75\">",
"       75",
"      </a>",
"      ]. Response to antipsychotic drug treatment is typically complete and occurs within two weeks of initiation of neuroleptics. Hypoalbuminemia may be a risk factor for glucocorticoid-induced psychosis in patients with systemic lupus erythematosus (SLE) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/77\">",
"       77",
"      </a>",
"      ]. Patients with SLE who are on higher doses present a particular problem, since it is often difficult to differentiate psychosis due to prednisone from neuropsychiatric lupus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of psychosis\", section on 'Substance induced psychotic disorder'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=see_link\">",
"       \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Memory impairment &mdash; Another report found that patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses of 5 to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for at least one year had a partial loss of explicit memory; older patients were more susceptible to memory impairment with less protracted treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/67,78\">",
"       67,78",
"      </a>",
"      ]. The effect on memory began as early as three months after the initiation of therapy. Approximately 1 percent of patients may be affected by more severe and persisting cognitive disturbances beginning during treatment with glucocorticoids that have been termed steroid dementia; in some patients, this condition may not remit for between 1 and 11 months after discontinuing the medication.",
"     </li>",
"     <li>",
"      Other symptoms &mdash; In a retrospective analysis involving 372,696 patients in general practices in the United Kingdom, there was a five- to sevenfold increased risk of completed or attempted suicide among patients receiving glucocorticoids, compared with patients with the same diagnoses who were not receiving such medications; however, the absolute risk was extremely low, approximating 0.1 cases per 100 patient-years of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/69\">",
"       69",
"      </a>",
"      ]. Younger patients were at higher risk. The observational nature of the study and potential for unknown confounding variables limits study interpretation.",
"      <br/>",
"      <br/>",
"      Rare cases of pseudotumor cerebri have been associated with glucocorticoid use, although higher doses are often effective in alleviating this generally self-limiting disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/79\">",
"       79",
"      </a>",
"      ]. Akathisia can occur even in patients taking low doses. An increased risk of panic disorder may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids cause a dose dependent, usually mild increase in fasting glucose levels and a greater increase in postprandial values in patients without pre-existing diabetes mellitus, but the development of de novo diabetes in a patient with initially normal glucose tolerance is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients with diabetes mellitus or glucose intolerance exhibit higher blood glucose levels while taking glucocorticoids, leading to increased difficulty with glycemic control. In addition, new-onset hyperglycemia or, rarely, a nonketotic hyperosmolar state or diabetic ketoacidosis develops without warning in patients with early subclinical diabetes or glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/60,80,81\">",
"     60,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids have a variety of actions that lead to hyperglycemia or an exacerbation of pre-existing diabetes. The mechanism by which glucocorticoids cause hyperglycemia is multifactorial, including augmentation of hepatic gluconeogenesis, inhibition of glucose uptake in adipose tissue, and alteration of receptor and post-receptor functions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/1,82-84\">",
"     1,82-84",
"    </a>",
"    ]. It is also possible that some underlying disorders for which glucocorticoids are used, such as rheumatoid arthritis, may independently predispose to a higher rate of glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of new onset diabetes following the initiation of glucocorticoid therapy was evaluated in a study of Medicaid recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/81\">",
"     81",
"    </a>",
"    ]. The relative risk of initiating glucose lowering therapy rose progressively with the glucocorticoid dose from 1.8 in patients treated with the equivalent of less than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to 10.3 in those with the equivalent of more than 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone. Risk factors for new onset hyperglycemia during glucocorticoid therapy are thought to be the same as those for other patients, including a family history of diabetes, increased age, obesity, and a history of gestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid-induced diabetes improves with reduction in the dose of glucocorticoid and usually reverses when the medication is stopped, although some patients develop persistent diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Transient hyperglycemia can occur after intraarticular glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Symptomatic diabetes mellitus, or asymptomatic but clinically significant hyperglycemia, that is glucocorticoid-induced is generally treated pharmacologically in the same way as it is in patients with diabetes mellitus or glucose intolerance in the absence of glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Glycemic control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of type 2 diabetes mellitus in children and adolescents\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6573898\">",
"    <span class=\"h2\">",
"     Infection and immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids have many effects upon innate and acquired immunity that predispose to infection, resulting in a dose-dependent increase in the risk of infection, especially with common bacterial, viral, and fungal pathogens. Glucocorticoids may be associated with a greater infection risk among patients with rheumatoid arthritis (RA), compared with other antirheumatic medications, such as the anti-TNF alpha agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/89\">",
"     89",
"    </a>",
"    ]. In one large study of RA patients, current and recent doses were most strongly associated with such risk, but the data also suggested a cumulative risk effect from doses taken during the preceding two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/90\">",
"     90",
"    </a>",
"    ]. The risk of infection with glucocorticoid therapy and the mechanisms underlying such risk are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to glucocorticoid dose, factors influencing infection risk include the underlying disorder, the presence of concomitant immunosuppressive therapies, and the location of the patient (ie, whether the patient is hospitalized). Older patients and those with lower functional status are also at higher risk for infection. In addition, patients taking glucocorticoids may not manifest signs and symptoms of infection as clearly, due to the inhibition of cytokine release and associated reduction in inflammatory and febrile responses. This can impair early recognition of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link&amp;anchor=H22#H22\">",
"     \"Glucocorticoid effects on the immune system\", section on 'Infection risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled and topical glucocorticoids are usually not implicated in increased risk of systemic infections, in contrast to the effects seen with systemic agents. The side effects of inhaled and topical glucocorticoids are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic doses of glucocorticoids often result in an increased white blood cell count (leukocytosis) that is due primarily to an increase in neutrophils (neutrophilia). This phenomenon is due to a decreased proportion of neutrophils that are adhering to the endothelium. This effect of glucocorticoids is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link&amp;anchor=H26#H26\">",
"     \"Causes of neutrophilia\", section on 'Glucocorticoids and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid dose and duration, as well the patient's underlying disease, appear to be important determining factors in predicting response to vaccination. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link&amp;anchor=H18#H18\">",
"     \"Glucocorticoid effects on the immune system\", section on 'Impact on vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety of live virus vaccines in specific patient groups is described briefly below but is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"     \"Medical management of immune deficiency\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=see_link&amp;anchor=H11#H11\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Vaccinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, live virus vaccines may be administered to patients who have taken:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      or its equivalent in doses of less than 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 14 days or less",
"     </li>",
"     <li>",
"      Glucocorticoids used for long-term physiologic replacement",
"     </li>",
"     <li>",
"      Glucocorticoids administered topically, by aerosol or by intraarticular, bursal or tendon injection, provided that there is no clinical or laboratory evidence of immunosuppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If higher doses of glucocorticoids are taken, MMR, Zoster, and other live virus vaccines should not be administered for one month after the cessation of glucocorticoid therapy. The immune response to other vaccines may be compromised by glucocorticoid administration in doses in excess of those noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343418\">",
"    <span class=\"h1\">",
"     MONITORING AND PREVENTION OF ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We try to limit the adverse effects of glucocorticoids by the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of the lowest dose of glucocorticoids for the shortest period of time needed to achieve the treatment goals",
"     </li>",
"     <li>",
"      Treatment of those pre-existing comorbid conditions that may increase risk when glucocorticoids are required",
"     </li>",
"     <li>",
"      Monitoring of patients under treatment for adverse effects that may benefit from additional intervention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pre-existing conditions or risk factors for adverse effects that should be assessed or treated when glucocorticoids are to be instituted include (see appropriate topic reviews) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/91\">",
"     91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Cataract or glaucoma",
"     </li>",
"     <li>",
"      Peptic ulcer disease",
"     </li>",
"     <li>",
"      Use of nonsteroidal antiinflammatory drugs",
"     </li>",
"     <li>",
"      Presence of infection",
"     </li>",
"     <li>",
"      Low bone density or osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of the monitoring performed in patients on glucocorticoids is already performed as part of the ongoing routine preventive care appropriate for age and the underlying medical condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During treatment with glucocorticoids and depending upon individual risk factors such as dose and duration of glucocorticoid usage, other medications being used, and comorbidities, particular attention should be given to (see appropriate topic reviews) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/47/27386/abstract/91\">",
"     91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body weight",
"     </li>",
"     <li>",
"      Blood pressure",
"     </li>",
"     <li>",
"      Heart failure and peripheral edema",
"     </li>",
"     <li>",
"      Serum lipids",
"     </li>",
"     <li>",
"      Diabetes or glucose intolerance",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Fracture risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H868596\">",
"    <span class=\"h1\">",
"     HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of exogenous glucocorticoids can suppress the hypothalamic-pituitary-adrenal axis (HPA). Abrupt cessation, or too rapid withdrawal, of glucocorticoids in such patients may cause symptoms of adrenal insufficiency. The approach to withdrawal of glucocorticoids, HPA suppression, and the clinical manifestations of adrenal insufficiency are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       \"Patient information: Steroid medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adverse effects (AE) of glucocorticoids are usually dose dependent, and many of the adverse effects, even of low doses, increase with greater duration of therapy. The effects and AE of glucocorticoids result from both genomic and nongenomic mechanisms that also have a role in the therapeutic effects of these agents. (See",
"      <a class=\"local\" href=\"#H24131064\">",
"       'Mechanism of adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common AEs include skin thinning and purpura; Cushingoid appearance and weight gain; sleep disturbance; and mood changes. Mood disorders, cognitive changes, and, rarely, psychosis may occur in patients on higher doses. Hyperglycemia or new onset diabetes mellitus is more common in patients with pre-existing diabetes or at risk of diabetes otherwise. Estimates of the frequency of particular adverse effects vary between studies and depend in part on the specific condition being treated and the glucocorticoid treatment regimen being used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Skin and soft tissues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Cushingoid appearance and weight gain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Central nervous system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Glucose metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cataracts are common with prolonged use (over a year) and are dose and duration dependent AE. Increased intraocular pressure is dose dependent but is also influenced by underlying risk. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Eye'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is evidence of increased risk of cardiovascular disease, but, in some settings, the use of antiinflammatory therapy, including glucocorticoids, may benefit the lipid profile. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Lipids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids at modest doses may cause increased blood pressure and, especially in patients with cardiac or renal disease, can cause fluid retention and peripheral edema. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Kidney and systemic hemodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased risk of peptic ulcer disease and gastritis in patients receiving glucocorticoids occurs primarily in patients concomitantly taking nonsteroidal antiinflammatory drugs. Such patients should receive appropriate prophylactic therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several potentially serious skeletal and muscle-related AEs may occur and are discussed in detail elsewhere. These include osteoporosis, increased fracture risk, osteonecrosis, myopathy, and, in children, effects on skeletal development and growth.",
"     </li>",
"     <li>",
"      Immunosuppression with increased risk of infection, neutrophilia, and the implications for vaccination are also discussed in detail separately. Patients receiving moderate- to high-dose glucocorticoids should generally not receive immunization with live virus vaccines. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Musculoskeletal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6573898\">",
"       'Infection and immune response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Neutrophilia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We try to limit the adverse effects of glucocorticoids by the following steps (see",
"      <a class=\"local\" href=\"#H343418\">",
"       'Monitoring and prevention of adverse effects'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Use of the lowest dose of glucocorticoids for the shortest period of time needed to achieve the treatment goals",
"     </li>",
"     <li>",
"      Treatment of those pre-existing comorbid conditions that may increase risk when glucocorticoids are required",
"     </li>",
"     <li>",
"      Monitoring of patients under treatment for adverse effects that may benefit from additional intervention",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/1\">",
"      Sch&auml;cke H, D&ouml;cke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/2\">",
"      Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/3\">",
"      Sch&auml;cke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/4\">",
"      Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/5\">",
"      Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/6\">",
"      McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994; 21:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/7\">",
"      Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/8\">",
"      Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/9\">",
"      Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/10\">",
"      Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/11\">",
"      Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/12\">",
"      Karagas MR, Cushing GL Jr, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/13\">",
"      S&oslash;rensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/14\">",
"      Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/15\">",
"      Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/16\">",
"      BLACK RL, OGLESBY RB, VON SALLMANN L, BUNIM JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960; 174:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/17\">",
"      Berkowitz JS, David DS, Sakai S, et al. Ocular complications in renal transplant recipients. Am J Med 1973; 55:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/18\">",
"      Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980; 98:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/19\">",
"      Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999; 15:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/20\">",
"      Long WF. A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom Physiol Opt 1977; 54:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/21\">",
"      Fran&ccedil;ois J. Corticosteroid glaucoma. Ophthalmologica 1984; 188:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/22\">",
"      Akingbehin AO. Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma. Br J Ophthalmol 1982; 66:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/23\">",
"      Slansky HH, Kolbert G, Gartner S. Exophathalmos induced by steroids. Arch Ophthalmol 1967; 77:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/24\">",
"      Crews SJ. Adverse Reactions to Corticosteroid Therapy in the Eye. Proc R Soc Med 1965; 58:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/25\">",
"      De Nijs E, Brabant P, De Laey JJ. The adverse effects of corticosteroids in central serous chorioretinopathy. Bull Soc Belge Ophtalmol 2003; :35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/26\">",
"      Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/27\">",
"      Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol 2004; 122:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/28\">",
"      Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/29\">",
"      Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/30\">",
"      Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/31\">",
"      Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007; 57:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/32\">",
"      Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012; 345:e4928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/33\">",
"      van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/34\">",
"      Huerta C, Lanes SF, Garc&iacute;a Rodr&iacute;guez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/35\">",
"      Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009; 169:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/36\">",
"      White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/37\">",
"      Svenson KL, Lithell H, H&auml;llgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/38\">",
"      Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 53:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/39\">",
"      Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/40\">",
"      Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/41\">",
"      MacGregor AJ, Dhillon VB, Binder A, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/42\">",
"      Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/43\">",
"      Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/44\">",
"      Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/45\">",
"      Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/46\">",
"      Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/47\">",
"      Glenn F, Grafe WR Jr. Surgical complications of adrenal steroid therapy. Ann Surg 1967; 165:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/48\">",
"      Sterioff S, Orringer MB, Cameron JL. Colon perforations associated with steroid therapy. Surgery 1974; 75:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/49\">",
"      Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004; 63:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/50\">",
"      Jones JP Jr, Engleman EP, Najarian JS. Systemic fat embolism after renal homotransplantation and treatment with corticosteroids. N Engl J Med 1965; 273:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/51\">",
"      HILL LW. Certain aspects of allergy in children. A critical review of the recent literature. N Engl J Med 1961; 265:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/52\">",
"      CARONE FA, LIEBOW AA. Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids. N Engl J Med 1957; 257:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/53\">",
"      Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993; 269:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/54\">",
"      Sadr-Azodi O, Mattsson F, Bexlius TS, et al. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. JAMA Intern Med 2013; 173:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/55\">",
"      Derk CT, DeHoratius RJ. Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol 2004; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/56\">",
"      Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. J Rheumatol 1998; 25:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/57\">",
"      Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992; 37:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/58\">",
"      Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/59\">",
"      Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/60\">",
"      Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/61\">",
"      Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981; 61 Suppl 7:381s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/62\">",
"      MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/63\">",
"      Crilly R, Cawood M, Marshall DH, Nordin BE. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 1978; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/64\">",
"      Kumagai S, Kawano S, Atsumi T, et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 2005; 32:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/65\">",
"      Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/66\">",
"      O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/67\">",
"      Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids. Mood, memory, and mechanisms. Ann N Y Acad Sci 2009; 1179:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/68\">",
"      Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry 2001; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/69\">",
"      Fardet L, Petersen I, Nazareth I. Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary Care. Am J Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/70\">",
"      Bolanos SH, Khan DA, Hanczyc M, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004; 92:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/71\">",
"      Swinburn CR, Wakefield JM, Newman SP, Jones PW. Evidence of prednisolone induced mood change ('steroid euphoria') in patients with chronic obstructive airways disease. Br J Clin Pharmacol 1988; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/72\">",
"      Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/73\">",
"      Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 1988; 38:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/74\">",
"      Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/75\">",
"      Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/76\">",
"      Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/77\">",
"      Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003; 61:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/78\">",
"      Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/79\">",
"      WALKER AE, ADAMKIEWICZ JJ. PSEUDOTUMOR CEREBRI ASSOCIATED WITH PROLONGED CORTICOSTEROID THERAPY. REPORTS OF FOUR CASES. JAMA 1964; 188:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/80\">",
"      Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976; 271:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/81\">",
"      Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/82\">",
"      McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/83\">",
"      Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 1980; 50:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/84\">",
"      Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. J Clin Invest 1984; 73:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/85\">",
"      Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and &beta;-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/86\">",
"      Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/87\">",
"      MILLER SE, NEILSON JM. CLINICAL FEATURES OF THE DIABETIC SYNDROME APPEARING AFTER STEROID THERAPY. Postgrad Med J 1964; 40:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/88\">",
"      Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/89\">",
"      Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-&alpha; antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/90\">",
"      Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/47/27386/abstract/91\">",
"      Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7988 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-2A8E9B1E90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27386=[""].join("\n");
var outline_f26_47_27386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24131064\">",
"      MECHANISM OF ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TOXICITY OF SYSTEMIC GLUCOCORTICOIDS BY ORGAN SYSTEM OR SYMPTOM COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Skin and soft tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cushingoid appearance and weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22923416\">",
"      - Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Kidney and systemic hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genitourinary and reproductive system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1676923\">",
"      - Vertebral fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Growth in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6573898\">",
"      Infection and immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H343418\">",
"      MONITORING AND PREVENTION OF ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H868596\">",
"      HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7988|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/45/20190\" title=\"figure 1\">",
"      Steroid side effects time dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/62/16365\" title=\"table 1\">",
"      Glucocorticoid side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=related_link\">",
"      Management of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_47_27387="Asthma adherence I";
var content_f26_47_27387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identifying problems in taking medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Review your medicine record",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Keep a record of when you take your medicines for about a week. In",
"addition to the time of day, write down where you are and what you are",
"doing. After a week, you can review the record and answer the following",
"questions to help you see where you are having problems:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Are times of day",
"related to problems in taking your medicine? What times are not",
"convenient? Did you miss a dose or take it late more than twice during",
"the week? Which doses were most often missed or late?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"some locations interfere with your medicine schedule? How often are you",
"away from home when you need to take your medicine? Does this cause a",
"problem? What locations cause the most problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"some activities interfere with your medicine schedule? What activities",
"have been related to missing or being late taking your medicines? Which",
"of these activities occur on a regular basis?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"other people interfere with your medicine schedule? Do you feel",
"embarrassed to take your medicine in front of certain people? Who? Do",
"people tell you that you don't need to take so much medicine? How often",
"do you see these people?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"moods or feelings interfere with your medicine schedule? What moods or",
"feelings cause problems? (For example, does feeling sad or discouraged",
"make you feel like taking your medicine?) How often and when do these",
"feelings occur?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27387=[""].join("\n");
var outline_f26_47_27387=null;
var title_f26_47_27388="Snellen visual acuity conversion";
var content_f26_47_27388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Snellen visual acuity conversions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        20 feet",
"       </td>",
"       <td class=\"subtitle1\">",
"        4 meters",
"       </td>",
"       <td class=\"subtitle1\">",
"        6 meters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/200",
"       </td>",
"       <td class=\"centered\">",
"        4/40",
"       </td>",
"       <td class=\"centered\">",
"        6/60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/160",
"       </td>",
"       <td class=\"centered\">",
"        4/32",
"       </td>",
"       <td class=\"centered\">",
"        6/48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/125",
"       </td>",
"       <td class=\"centered\">",
"        4/25",
"       </td>",
"       <td class=\"centered\">",
"        6/38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/100",
"       </td>",
"       <td class=\"centered\">",
"        4/20",
"       </td>",
"       <td class=\"centered\">",
"        6/30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/80",
"       </td>",
"       <td class=\"centered\">",
"        4/16",
"       </td>",
"       <td class=\"centered\">",
"        6/24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/63",
"       </td>",
"       <td class=\"centered\">",
"        4/12.6",
"       </td>",
"       <td class=\"centered\">",
"        6/20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/50",
"       </td>",
"       <td class=\"centered\">",
"        4/10",
"       </td>",
"       <td class=\"centered\">",
"        6/15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/40",
"       </td>",
"       <td class=\"centered\">",
"        4/8",
"       </td>",
"       <td class=\"centered\">",
"        6/12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/32",
"       </td>",
"       <td class=\"centered\">",
"        4/6.3",
"       </td>",
"       <td class=\"centered\">",
"        6/10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/25",
"       </td>",
"       <td class=\"centered\">",
"        4/5",
"       </td>",
"       <td class=\"centered\">",
"        6/7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/20",
"       </td>",
"       <td class=\"centered\">",
"        4/4",
"       </td>",
"       <td class=\"centered\">",
"        6/6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/16",
"       </td>",
"       <td class=\"centered\">",
"        4/3.2",
"       </td>",
"       <td class=\"centered\">",
"        6/5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/12.5",
"       </td>",
"       <td class=\"centered\">",
"        4/2.5",
"       </td>",
"       <td class=\"centered\">",
"        6/3.75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20/10",
"       </td>",
"       <td class=\"centered\">",
"        4/2",
"       </td>",
"       <td class=\"centered\">",
"        6/3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94:91.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27388=[""].join("\n");
var outline_f26_47_27388=null;
var title_f26_47_27389="Contents: Impulse control disorders";
var content_f26_47_27389=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Impulse control disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Impulse control disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/44/15049\">",
"           Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26760\">",
"           Intermittent explosive disorder in adults: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22760\">",
"           Pathologic gambling",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-C293D716A6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_47_27389=[""].join("\n");
var outline_f26_47_27389=null;
var title_f26_47_27390="Detection Rx ischemic CMP";
var content_f26_47_27390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm to detect potentially reversible ischemic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 488px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Choice of imaging study varies with local expertise and availability and cost.",
"     <br>",
"      &bull; Depends upon age, comorbidities, prior revascularization, and patient preference.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. J Am Coll Cardiol 2005; 46:567.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27390=[""].join("\n");
var outline_f26_47_27390=null;
var title_f26_47_27391="RUL RML atelectasis-III";
var content_f26_47_27391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral chest radiograph reveals combined atelectasis of the right upper and right middle lobes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wedge-shaped opacity (arrow) descends from the upper lung toward the cardiac silhouette. The right major fissure is deviated anteriorly. The retrosternal lucency is accounted for by hyperexpansion of the left upper lobe (asterisk).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_47_27391=[""].join("\n");
var outline_f26_47_27391=null;
  